Middle East respiratory syndrome vaccines
Identifieur interne : 000D59 ( Pmc/Corpus ); précédent : 000D58; suivant : 000D60Middle East respiratory syndrome vaccines
Auteurs : Stanley Perlman ; Rahul VijaySource :
- International Journal of Infectious Diseases [ 1201-9712 ] ; 2016.
Abstract
Middle East respiratory syndrome (MERS), caused by a novel coronavirus, is a highly lethal respiratory disease. No vaccines or antiviral therapies are available. Camels are widely infected and may be good targets for vaccination. MERS monoclonal antibodies and human convalescent sera may be useful for prophylaxis and treatment. Active immunization strategies, based on the severe acute respiratory syndrome (SARS) experience, are under development.
Url:
DOI: 10.1016/j.ijid.2016.04.008
PubMed: 27062985
PubMed Central: 4969153
Links to Exploration step
PMC:4969153Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Middle East respiratory syndrome vaccines</title><author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name></author><author><name sortKey="Vijay, Rahul" sort="Vijay, Rahul" uniqKey="Vijay R" first="Rahul" last="Vijay">Rahul Vijay</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27062985</idno><idno type="pmc">4969153</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969153</idno><idno type="RBID">PMC:4969153</idno><idno type="doi">10.1016/j.ijid.2016.04.008</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000D59</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000D59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Middle East respiratory syndrome vaccines</title><author><name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name></author><author><name sortKey="Vijay, Rahul" sort="Vijay, Rahul" uniqKey="Vijay R" first="Rahul" last="Vijay">Rahul Vijay</name></author></analytic><series><title level="j">International Journal of Infectious Diseases</title><idno type="ISSN">1201-9712</idno><idno type="eISSN">1878-3511</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>•</label><p id="par0005">Middle East respiratory syndrome (MERS), caused by a novel coronavirus, is a highly lethal respiratory disease.</p></list-item><list-item id="lsti0010"><label>•</label><p id="par0010">No vaccines or antiviral therapies are available.</p></list-item><list-item id="lsti0015"><label>•</label><p id="par0015">Camels are widely infected and may be good targets for vaccination.</p></list-item><list-item id="lsti0020"><label>•</label><p id="par0020">MERS monoclonal antibodies and human convalescent sera may be useful for prophylaxis and treatment.</p></list-item><list-item id="lsti0025"><label>•</label><p id="par0025">Active immunization strategies, based on the severe acute respiratory syndrome (SARS) experience, are under development.</p></list-item></list></p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Zaki, A M" uniqKey="Zaki A">A.M. Zaki</name></author><author><name sortKey="Van Boheemen, S" uniqKey="Van Boheemen S">S. van Boheemen</name></author><author><name sortKey="Bestebroer, T M" uniqKey="Bestebroer T">T.M. Bestebroer</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author><author><name sortKey="Fouchier, R A" uniqKey="Fouchier R">R.A. Fouchier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zumla, A" uniqKey="Zumla A">A. Zumla</name></author><author><name sortKey="Hui, D S" uniqKey="Hui D">D.S. Hui</name></author><author><name sortKey="Perlman, S" uniqKey="Perlman S">S. Perlman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name></author><author><name sortKey="Jores, J" uniqKey="Jores J">J. Jores</name></author><author><name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name></author><author><name sortKey="Younan, M" uniqKey="Younan M">M. Younan</name></author><author><name sortKey="Liljander, A" uniqKey="Liljander A">A. Liljander</name></author><author><name sortKey="Said, M Y" uniqKey="Said M">M.Y. Said</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hemida, M G" uniqKey="Hemida M">M.G. Hemida</name></author><author><name sortKey="Chu, D K" uniqKey="Chu D">D.K. Chu</name></author><author><name sortKey="Poon, L L" uniqKey="Poon L">L.L. Poon</name></author><author><name sortKey="Perera, R A" uniqKey="Perera R">R.A. Perera</name></author><author><name sortKey="Alhammadi, M A" uniqKey="Alhammadi M">M.A. Alhammadi</name></author><author><name sortKey="Ng, H Y" uniqKey="Ng H">H.Y. Ng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muller, M A" uniqKey="Muller M">M.A. Müller</name></author><author><name sortKey="Corman, V M" uniqKey="Corman V">V.M. Corman</name></author><author><name sortKey="Jores, J" uniqKey="Jores J">J. Jores</name></author><author><name sortKey="Meyer, B" uniqKey="Meyer B">B. Meyer</name></author><author><name sortKey="Younan, M" uniqKey="Younan M">M. Younan</name></author><author><name sortKey="Lijander, A" uniqKey="Lijander A">A. Lijander</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sabir, J S" uniqKey="Sabir J">J.S. Sabir</name></author><author><name sortKey="Lam, T T" uniqKey="Lam T">T.T. Lam</name></author><author><name sortKey="Ahmed, M M" uniqKey="Ahmed M">M.M. Ahmed</name></author><author><name sortKey="Li, L" uniqKey="Li L">L. Li</name></author><author><name sortKey="Shen, Y" uniqKey="Shen Y">Y. Shen</name></author><author><name sortKey="Abo Aba, S E" uniqKey="Abo Aba S">S.E. Abo-Aba</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Masters, P S" uniqKey="Masters P">P.S. Masters</name></author><author><name sortKey="Perlman, S" uniqKey="Perlman S">S. Perlman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cotten, M" uniqKey="Cotten M">M. Cotten</name></author><author><name sortKey="Watson, S J" uniqKey="Watson S">S.J. Watson</name></author><author><name sortKey="Zumla, A I" uniqKey="Zumla A">A.I. Zumla</name></author><author><name sortKey="Makhdoom, H Q" uniqKey="Makhdoom H">H.Q. Makhdoom</name></author><author><name sortKey="Palser, A L" uniqKey="Palser A">A.L. Palser</name></author><author><name sortKey="Ong, S H" uniqKey="Ong S">S.H. Ong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Al Abdallat, M M" uniqKey="Al Abdallat M">M.M. Al-Abdallat</name></author><author><name sortKey="Payne, D C" uniqKey="Payne D">D.C. Payne</name></author><author><name sortKey="Alqasrawi, S" uniqKey="Alqasrawi S">S. Alqasrawi</name></author><author><name sortKey="Rha, B" uniqKey="Rha B">B. Rha</name></author><author><name sortKey="Tohme, R A" uniqKey="Tohme R">R.A. Tohme</name></author><author><name sortKey="Abedi, G R" uniqKey="Abedi G">G.R. Abedi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oboho, I K" uniqKey="Oboho I">I.K. Oboho</name></author><author><name sortKey="Tomczyk, S M" uniqKey="Tomczyk S">S.M. Tomczyk</name></author><author><name sortKey="Al Asmari, A M" uniqKey="Al Asmari A">A.M. Al-Asmari</name></author><author><name sortKey="Banjar, A A" uniqKey="Banjar A">A.A. Banjar</name></author><author><name sortKey="Al Mugti, H" uniqKey="Al Mugti H">H. Al-Mugti</name></author><author><name sortKey="Aloraini, M S" uniqKey="Aloraini M">M.S. Aloraini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bergmann, C C" uniqKey="Bergmann C">C.C. Bergmann</name></author><author><name sortKey="Lane, T E" uniqKey="Lane T">T.E. Lane</name></author><author><name sortKey="Stohlman, S A" uniqKey="Stohlman S">S.A. Stohlman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L. Du</name></author><author><name sortKey="He, Y" uniqKey="He Y">Y. He</name></author><author><name sortKey="Zhou, Y" uniqKey="Zhou Y">Y. Zhou</name></author><author><name sortKey="Liu, S" uniqKey="Liu S">S. Liu</name></author><author><name sortKey="Zheng, B J" uniqKey="Zheng B">B.J. Zheng</name></author><author><name sortKey="Jiang, S" uniqKey="Jiang S">S. Jiang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sheahan, T" uniqKey="Sheahan T">T. Sheahan</name></author><author><name sortKey="Rockx, B" uniqKey="Rockx B">B. Rockx</name></author><author><name sortKey="Donaldson, E" uniqKey="Donaldson E">E. Donaldson</name></author><author><name sortKey="Sims, A" uniqKey="Sims A">A. Sims</name></author><author><name sortKey="Pickles, R" uniqKey="Pickles R">R. Pickles</name></author><author><name sortKey="Corti, D" uniqKey="Corti D">D. Corti</name></author><author><name sortKey="Baric, R" uniqKey="Baric R">R. Baric</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Williamson, J S" uniqKey="Williamson J">J.S. Williamson</name></author><author><name sortKey="Stohlman, S A" uniqKey="Stohlman S">S.A. Stohlman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, F" uniqKey="Wang F">F. Wang</name></author><author><name sortKey="Stohlman, S A" uniqKey="Stohlman S">S.A. Stohlman</name></author><author><name sortKey="Fleming, J O" uniqKey="Fleming J">J.O. Fleming</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, G F" uniqKey="Wu G">G.F. Wu</name></author><author><name sortKey="Dandekar, A A" uniqKey="Dandekar A">A.A. Dandekar</name></author><author><name sortKey="Pewe, L" uniqKey="Pewe L">L. Pewe</name></author><author><name sortKey="Perlman, S" uniqKey="Perlman S">S. Perlman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ramakrishna, C" uniqKey="Ramakrishna C">C. Ramakrishna</name></author><author><name sortKey="Stohlman, S A" uniqKey="Stohlman S">S.A. Stohlman</name></author><author><name sortKey="Atkinson, R D" uniqKey="Atkinson R">R.D. Atkinson</name></author><author><name sortKey="Shlomchik, M J" uniqKey="Shlomchik M">M.J. Shlomchik</name></author><author><name sortKey="Bergmann, C C" uniqKey="Bergmann C">C.C. Bergmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bradburne, A F" uniqKey="Bradburne A">A.F. Bradburne</name></author><author><name sortKey="Somerset, B A" uniqKey="Somerset B">B.A. Somerset</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Callow, K A" uniqKey="Callow K">K.A. Callow</name></author><author><name sortKey="Parry, H F" uniqKey="Parry H">H.F. Parry</name></author><author><name sortKey="Sergeant, M" uniqKey="Sergeant M">M. Sergeant</name></author><author><name sortKey="Tyrrell, D A" uniqKey="Tyrrell D">D.A. Tyrrell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peiris, J S" uniqKey="Peiris J">J.S. Peiris</name></author><author><name sortKey="Yuen, K Y" uniqKey="Yuen K">K.Y. Yuen</name></author><author><name sortKey="Osterhaus, A D" uniqKey="Osterhaus A">A.D. Osterhaus</name></author><author><name sortKey="Stohr, K" uniqKey="Stohr K">K. Stohr</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tang, F" uniqKey="Tang F">F. Tang</name></author><author><name sortKey="Quan, Y" uniqKey="Quan Y">Y. Quan</name></author><author><name sortKey="Xin, Z T" uniqKey="Xin Z">Z.T. Xin</name></author><author><name sortKey="Wrammert, J" uniqKey="Wrammert J">J. Wrammert</name></author><author><name sortKey="Ma, M J" uniqKey="Ma M">M.J. Ma</name></author><author><name sortKey="Lv, H" uniqKey="Lv H">H. Lv</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fan, Y Y" uniqKey="Fan Y">Y.Y. Fan</name></author><author><name sortKey="Huang, Z T" uniqKey="Huang Z">Z.T. Huang</name></author><author><name sortKey="Li, L" uniqKey="Li L">L. Li</name></author><author><name sortKey="Wu, M H" uniqKey="Wu M">M.H. Wu</name></author><author><name sortKey="Yu, T" uniqKey="Yu T">T. Yu</name></author><author><name sortKey="Koup, R A" uniqKey="Koup R">R.A. Koup</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peng, H" uniqKey="Peng H">H. Peng</name></author><author><name sortKey="Yang, L T" uniqKey="Yang L">L.T. Yang</name></author><author><name sortKey="Wang, L Y" uniqKey="Wang L">L.Y. Wang</name></author><author><name sortKey="Li, J" uniqKey="Li J">J. Li</name></author><author><name sortKey="Huang, J" uniqKey="Huang J">J. Huang</name></author><author><name sortKey="Lu, Z Q" uniqKey="Lu Z">Z.Q. Lu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, L T" uniqKey="Yang L">L.T. Yang</name></author><author><name sortKey="Peng, H" uniqKey="Peng H">H. Peng</name></author><author><name sortKey="Zhu, Z L" uniqKey="Zhu Z">Z.L. Zhu</name></author><author><name sortKey="Li, G" uniqKey="Li G">G. Li</name></author><author><name sortKey="Huang, Z T" uniqKey="Huang Z">Z.T. Huang</name></author><author><name sortKey="Zhao, Z X" uniqKey="Zhao Z">Z.X. Zhao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cavanagh, D" uniqKey="Cavanagh D">D. Cavanagh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saif, L J" uniqKey="Saif L">L.J. Saif</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schwegmann Wessels, C" uniqKey="Schwegmann Wessels C">C. Schwegmann-Wessels</name></author><author><name sortKey="Herrler, G" uniqKey="Herrler G">G. Herrler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pedersen, N C" uniqKey="Pedersen N">N.C. Pedersen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vennema, H" uniqKey="Vennema H">H. Vennema</name></author><author><name sortKey="De Groot, R J" uniqKey="De Groot R">R.J. de Groot</name></author><author><name sortKey="Harbour, D A" uniqKey="Harbour D">D.A. Harbour</name></author><author><name sortKey="Dalderup, M" uniqKey="Dalderup M">M. Dalderup</name></author><author><name sortKey="Gruffydd Jones, T" uniqKey="Gruffydd Jones T">T. Gruffydd-Jones</name></author><author><name sortKey="Horzinek, M C" uniqKey="Horzinek M">M.C. Horzinek</name></author><author><name sortKey="Spaan, W J" uniqKey="Spaan W">W.J. Spaan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Z Y" uniqKey="Yang Z">Z.Y. Yang</name></author><author><name sortKey="Werner, H C" uniqKey="Werner H">H.C. Werner</name></author><author><name sortKey="Kong, W P" uniqKey="Kong W">W.P. Kong</name></author><author><name sortKey="Leung, K" uniqKey="Leung K">K. Leung</name></author><author><name sortKey="Traggiai, E" uniqKey="Traggiai E">E. Traggiai</name></author><author><name sortKey="Lanzavecchia, A" uniqKey="Lanzavecchia A">A. Lanzavecchia</name></author><author><name sortKey="Nabel, G J" uniqKey="Nabel G">G.J. Nabel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu, Z" uniqKey="Zhu Z">Z. Zhu</name></author><author><name sortKey="Chakraborti, S" uniqKey="Chakraborti S">S. Chakraborti</name></author><author><name sortKey="He, Y" uniqKey="He Y">Y. He</name></author><author><name sortKey="Roberts, A" uniqKey="Roberts A">A. Roberts</name></author><author><name sortKey="Sheahan, T" uniqKey="Sheahan T">T. Sheahan</name></author><author><name sortKey="Xiao, X" uniqKey="Xiao X">X. Xiao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sui, J" uniqKey="Sui J">J. Sui</name></author><author><name sortKey="Li, W" uniqKey="Li W">W. Li</name></author><author><name sortKey="Murakami, A" uniqKey="Murakami A">A. Murakami</name></author><author><name sortKey="Tamin, A" uniqKey="Tamin A">A. Tamin</name></author><author><name sortKey="Matthews, L J" uniqKey="Matthews L">L.J. Matthews</name></author><author><name sortKey="Wong, S K" uniqKey="Wong S">S.K. Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Traggiai, E" uniqKey="Traggiai E">E. Traggiai</name></author><author><name sortKey="Becker, S" uniqKey="Becker S">S. Becker</name></author><author><name sortKey="Subbarao, K" uniqKey="Subbarao K">K. Subbarao</name></author><author><name sortKey="Kolesnikova, L" uniqKey="Kolesnikova L">L. Kolesnikova</name></author><author><name sortKey="Uematsu, Y" uniqKey="Uematsu Y">Y. Uematsu</name></author><author><name sortKey="Gismondo, M R" uniqKey="Gismondo M">M.R. Gismondo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stockman, L J" uniqKey="Stockman L">L.J. Stockman</name></author><author><name sortKey="Bellamy, R" uniqKey="Bellamy R">R. Bellamy</name></author><author><name sortKey="Garner, P" uniqKey="Garner P">P. Garner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mair Jenkins, J" uniqKey="Mair Jenkins J">J. Mair-Jenkins</name></author><author><name sortKey="Saavedra Campos, M" uniqKey="Saavedra Campos M">M. Saavedra-Campos</name></author><author><name sortKey="Baillie, J K" uniqKey="Baillie J">J.K. Baillie</name></author><author><name sortKey="Cleary, P" uniqKey="Cleary P">P. Cleary</name></author><author><name sortKey="Khaw, F M" uniqKey="Khaw F">F.M. Khaw</name></author><author><name sortKey="Lim, W S" uniqKey="Lim W">W.S. Lim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jiang, L" uniqKey="Jiang L">L. Jiang</name></author><author><name sortKey="Wang, N" uniqKey="Wang N">N. Wang</name></author><author><name sortKey="Zuo, T" uniqKey="Zuo T">T. Zuo</name></author><author><name sortKey="Shi, X" uniqKey="Shi X">X. Shi</name></author><author><name sortKey="Poon, K M" uniqKey="Poon K">K.M. Poon</name></author><author><name sortKey="Wu, Y" uniqKey="Wu Y">Y. Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tang, X C" uniqKey="Tang X">X.C. Tang</name></author><author><name sortKey="Agnihothram, S S" uniqKey="Agnihothram S">S.S. Agnihothram</name></author><author><name sortKey="Jiao, Y" uniqKey="Jiao Y">Y. Jiao</name></author><author><name sortKey="Stanhope, J" uniqKey="Stanhope J">J. Stanhope</name></author><author><name sortKey="Graham, R L" uniqKey="Graham R">R.L. Graham</name></author><author><name sortKey="Peterson, E C" uniqKey="Peterson E">E.C. Peterson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ying, T" uniqKey="Ying T">T. Ying</name></author><author><name sortKey="Du, L" uniqKey="Du L">L. Du</name></author><author><name sortKey="Ju, T W" uniqKey="Ju T">T.W. Ju</name></author><author><name sortKey="Prabakaran, P" uniqKey="Prabakaran P">P. Prabakaran</name></author><author><name sortKey="Lau, C C" uniqKey="Lau C">C.C. Lau</name></author><author><name sortKey="Lu, L" uniqKey="Lu L">L. Lu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corti, D" uniqKey="Corti D">D. Corti</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J. Zhao</name></author><author><name sortKey="Pedotti, M" uniqKey="Pedotti M">M. Pedotti</name></author><author><name sortKey="Simonelli, L" uniqKey="Simonelli L">L. Simonelli</name></author><author><name sortKey="Agnihothram, S" uniqKey="Agnihothram S">S. Agnihothram</name></author><author><name sortKey="Fett, C" uniqKey="Fett C">C. Fett</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, J" uniqKey="Zhao J">J. Zhao</name></author><author><name sortKey="Li, K" uniqKey="Li K">K. Li</name></author><author><name sortKey="Wohlford Lenane, C" uniqKey="Wohlford Lenane C">C. Wohlford-Lenane</name></author><author><name sortKey="Agnihothram, S S" uniqKey="Agnihothram S">S.S. Agnihothram</name></author><author><name sortKey="Fett, C" uniqKey="Fett C">C. Fett</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J. Zhao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pascal, K E" uniqKey="Pascal K">K.E. Pascal</name></author><author><name sortKey="Coleman, C M" uniqKey="Coleman C">C.M. Coleman</name></author><author><name sortKey="Mujica, A O" uniqKey="Mujica A">A.O. Mujica</name></author><author><name sortKey="Kamat, V" uniqKey="Kamat V">V. Kamat</name></author><author><name sortKey="Badithe, A" uniqKey="Badithe A">A. Badithe</name></author><author><name sortKey="Fairhurst, J" uniqKey="Fairhurst J">J. Fairhurst</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, J" uniqKey="Zhao J">J. Zhao</name></author><author><name sortKey="Perera, R A" uniqKey="Perera R">R.A. Perera</name></author><author><name sortKey="Kayali, G" uniqKey="Kayali G">G. Kayali</name></author><author><name sortKey="Meyerholz, D" uniqKey="Meyerholz D">D. Meyerholz</name></author><author><name sortKey="Perlman, S" uniqKey="Perlman S">S. Perlman</name></author><author><name sortKey="Peiris, M" uniqKey="Peiris M">M. Peiris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martin, J E" uniqKey="Martin J">J.E. Martin</name></author><author><name sortKey="Louder, M K" uniqKey="Louder M">M.K. Louder</name></author><author><name sortKey="Holman, L A" uniqKey="Holman L">L.A. Holman</name></author><author><name sortKey="Gordon, I J" uniqKey="Gordon I">I.J. Gordon</name></author><author><name sortKey="Enama, M E" uniqKey="Enama M">M.E. Enama</name></author><author><name sortKey="Larkin, B D" uniqKey="Larkin B">B.D. Larkin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Z Y" uniqKey="Yang Z">Z.Y. Yang</name></author><author><name sortKey="Kong, W P" uniqKey="Kong W">W.P. Kong</name></author><author><name sortKey="Huang, Y" uniqKey="Huang Y">Y. Huang</name></author><author><name sortKey="Roberts, A" uniqKey="Roberts A">A. Roberts</name></author><author><name sortKey="Murphy, B R" uniqKey="Murphy B">B.R. Murphy</name></author><author><name sortKey="Subbarao, K" uniqKey="Subbarao K">K. Subbarao</name></author><author><name sortKey="Nabel, G J" uniqKey="Nabel G">G.J. Nabel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, J T" uniqKey="Lin J">J.T. Lin</name></author><author><name sortKey="Zhang, J S" uniqKey="Zhang J">J.S. Zhang</name></author><author><name sortKey="Su, N" uniqKey="Su N">N. Su</name></author><author><name sortKey="Xu, J G" uniqKey="Xu J">J.G. Xu</name></author><author><name sortKey="Wang, N" uniqKey="Wang N">N. Wang</name></author><author><name sortKey="Chen, J T" uniqKey="Chen J">J.T. Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He, Y" uniqKey="He Y">Y. He</name></author><author><name sortKey="Zhou, Y" uniqKey="Zhou Y">Y. Zhou</name></author><author><name sortKey="Siddiqui, P" uniqKey="Siddiqui P">P. Siddiqui</name></author><author><name sortKey="Jiang, S" uniqKey="Jiang S">S. Jiang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bolles, M" uniqKey="Bolles M">M. Bolles</name></author><author><name sortKey="Deming, D" uniqKey="Deming D">D. Deming</name></author><author><name sortKey="Long, K" uniqKey="Long K">K. Long</name></author><author><name sortKey="Agnihothram, S" uniqKey="Agnihothram S">S. Agnihothram</name></author><author><name sortKey="Whitmore, A" uniqKey="Whitmore A">A. Whitmore</name></author><author><name sortKey="Ferris, M" uniqKey="Ferris M">M. Ferris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tseng, C T" uniqKey="Tseng C">C.T. Tseng</name></author><author><name sortKey="Sbrana, E" uniqKey="Sbrana E">E. Sbrana</name></author><author><name sortKey="Iwata Yoshikawa, N" uniqKey="Iwata Yoshikawa N">N. Iwata-Yoshikawa</name></author><author><name sortKey="Newman, P C" uniqKey="Newman P">P.C. Newman</name></author><author><name sortKey="Garron, T" uniqKey="Garron T">T. Garron</name></author><author><name sortKey="Atmar, R L" uniqKey="Atmar R">R.L. Atmar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Almazan, F" uniqKey="Almazan F">F. Almazan</name></author><author><name sortKey="Dediego, M L" uniqKey="Dediego M">M.L. Dediego</name></author><author><name sortKey="Galan, C" uniqKey="Galan C">C. Galan</name></author><author><name sortKey="Escors, D" uniqKey="Escors D">D. Escors</name></author><author><name sortKey="Alvarez, E" uniqKey="Alvarez E">E. Alvarez</name></author><author><name sortKey="Ortego, J" uniqKey="Ortego J">J. Ortego</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yount, B" uniqKey="Yount B">B. Yount</name></author><author><name sortKey="Curtis, K M" uniqKey="Curtis K">K.M. Curtis</name></author><author><name sortKey="Fritz, E A" uniqKey="Fritz E">E.A. Fritz</name></author><author><name sortKey="Hensley, L E" uniqKey="Hensley L">L.E. Hensley</name></author><author><name sortKey="Jahrling, P B" uniqKey="Jahrling P">P.B. Jahrling</name></author><author><name sortKey="Prentice, E" uniqKey="Prentice E">E. Prentice</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dediego, M L" uniqKey="Dediego M">M.L. DeDiego</name></author><author><name sortKey="Alvarez, E" uniqKey="Alvarez E">E. Alvarez</name></author><author><name sortKey="Almazan, F" uniqKey="Almazan F">F. Almazan</name></author><author><name sortKey="Rejas, M T" uniqKey="Rejas M">M.T. Rejas</name></author><author><name sortKey="Lamirande, E" uniqKey="Lamirande E">E. Lamirande</name></author><author><name sortKey="Roberts, A" uniqKey="Roberts A">A. Roberts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lamirande, E W" uniqKey="Lamirande E">E.W. Lamirande</name></author><author><name sortKey="Dediego, M L" uniqKey="Dediego M">M.L. DeDiego</name></author><author><name sortKey="Roberts, A" uniqKey="Roberts A">A. Roberts</name></author><author><name sortKey="Jackson, J P" uniqKey="Jackson J">J.P. Jackson</name></author><author><name sortKey="Alvarez, E" uniqKey="Alvarez E">E. Alvarez</name></author><author><name sortKey="Sheahan, T" uniqKey="Sheahan T">T. Sheahan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Netland, J" uniqKey="Netland J">J. Netland</name></author><author><name sortKey="Dediego, M L" uniqKey="Dediego M">M.L. DeDiego</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J. Zhao</name></author><author><name sortKey="Fett, C" uniqKey="Fett C">C. Fett</name></author><author><name sortKey="Alvarez, E" uniqKey="Alvarez E">E. Alvarez</name></author><author><name sortKey="Nieto Torres, J L" uniqKey="Nieto Torres J">J.L. Nieto-Torres</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jimenez Guardeno, J M" uniqKey="Jimenez Guardeno J">J.M. Jimenez-Guardeno</name></author><author><name sortKey="Regla Nava, J A" uniqKey="Regla Nava J">J.A. Regla-Nava</name></author><author><name sortKey="Nieto Torres, J L" uniqKey="Nieto Torres J">J.L. Nieto-Torres</name></author><author><name sortKey="Dediego, M L" uniqKey="Dediego M">M.L. DeDiego</name></author><author><name sortKey="Castano Rodriguez, C" uniqKey="Castano Rodriguez C">C. Castano-Rodriguez</name></author><author><name sortKey="Fernandez Delgado, R" uniqKey="Fernandez Delgado R">R. Fernandez-Delgado</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Graham, R L" uniqKey="Graham R">R.L. Graham</name></author><author><name sortKey="Becker, M M" uniqKey="Becker M">M.M. Becker</name></author><author><name sortKey="Eckerle, L D" uniqKey="Eckerle L">L.D. Eckerle</name></author><author><name sortKey="Bolles, M" uniqKey="Bolles M">M. Bolles</name></author><author><name sortKey="Denison, M R" uniqKey="Denison M">M.R. Denison</name></author><author><name sortKey="Baric, R S" uniqKey="Baric R">R.S. Baric</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yount, B" uniqKey="Yount B">B. Yount</name></author><author><name sortKey="Roberts, R S" uniqKey="Roberts R">R.S. Roberts</name></author><author><name sortKey="Lindesmith, L" uniqKey="Lindesmith L">L. Lindesmith</name></author><author><name sortKey="Baric, R S" uniqKey="Baric R">R.S. Baric</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zust, R" uniqKey="Zust R">R. Zust</name></author><author><name sortKey="Cervantes Barragan, L" uniqKey="Cervantes Barragan L">L. Cervantes-Barragan</name></author><author><name sortKey="Kuri, T" uniqKey="Kuri T">T. Kuri</name></author><author><name sortKey="Blakqori, G" uniqKey="Blakqori G">G. Blakqori</name></author><author><name sortKey="Weber, F" uniqKey="Weber F">F. Weber</name></author><author><name sortKey="Ludewig, B" uniqKey="Ludewig B">B. Ludewig</name></author><author><name sortKey="Thiel, V" uniqKey="Thiel V">V. Thiel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bisht, H" uniqKey="Bisht H">H. Bisht</name></author><author><name sortKey="Roberts, A" uniqKey="Roberts A">A. Roberts</name></author><author><name sortKey="Vogel, L" uniqKey="Vogel L">L. Vogel</name></author><author><name sortKey="Bukreyev, A" uniqKey="Bukreyev A">A. Bukreyev</name></author><author><name sortKey="Collins, P L" uniqKey="Collins P">P.L. Collins</name></author><author><name sortKey="Murphy, B R" uniqKey="Murphy B">B.R. Murphy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="See, R H" uniqKey="See R">R.H. See</name></author><author><name sortKey="Petric, M" uniqKey="Petric M">M. Petric</name></author><author><name sortKey="Lawrence, D J" uniqKey="Lawrence D">D.J. Lawrence</name></author><author><name sortKey="Mok, C P" uniqKey="Mok C">C.P. Mok</name></author><author><name sortKey="Rowe, T" uniqKey="Rowe T">T. Rowe</name></author><author><name sortKey="Zitzow, L A" uniqKey="Zitzow L">L.A. Zitzow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kobinger, G P" uniqKey="Kobinger G">G.P. Kobinger</name></author><author><name sortKey="Figueredo, J M" uniqKey="Figueredo J">J.M. Figueredo</name></author><author><name sortKey="Rowe, T" uniqKey="Rowe T">T. Rowe</name></author><author><name sortKey="Zhi, Y" uniqKey="Zhi Y">Y. Zhi</name></author><author><name sortKey="Gao, G" uniqKey="Gao G">G. Gao</name></author><author><name sortKey="Sanmiguel, J C" uniqKey="Sanmiguel J">J.C. Sanmiguel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L. Du</name></author><author><name sortKey="Zhao, G" uniqKey="Zhao G">G. Zhao</name></author><author><name sortKey="Lin, Y" uniqKey="Lin Y">Y. Lin</name></author><author><name sortKey="Sui, H" uniqKey="Sui H">H. Sui</name></author><author><name sortKey="Chan, C" uniqKey="Chan C">C. Chan</name></author><author><name sortKey="Ma, S" uniqKey="Ma S">S. Ma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bukreyev, A" uniqKey="Bukreyev A">A. Bukreyev</name></author><author><name sortKey="Lamirande, E W" uniqKey="Lamirande E">E.W. Lamirande</name></author><author><name sortKey="Buchholz, U J" uniqKey="Buchholz U">U.J. Buchholz</name></author><author><name sortKey="Vogel, L N" uniqKey="Vogel L">L.N. Vogel</name></author><author><name sortKey="Elkins, W R" uniqKey="Elkins W">W.R. Elkins</name></author><author><name sortKey="St Claire, M" uniqKey="St Claire M">M. St Claire</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Faber, M" uniqKey="Faber M">M. Faber</name></author><author><name sortKey="Lamirande, E W" uniqKey="Lamirande E">E.W. Lamirande</name></author><author><name sortKey="Roberts, A" uniqKey="Roberts A">A. Roberts</name></author><author><name sortKey="Rice, A B" uniqKey="Rice A">A.B. Rice</name></author><author><name sortKey="Koprowski, H" uniqKey="Koprowski H">H. Koprowski</name></author><author><name sortKey="Dietzschold, B" uniqKey="Dietzschold B">B. Dietzschold</name></author><author><name sortKey="Schnell, M J" uniqKey="Schnell M">M.J. Schnell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Escriou, N" uniqKey="Escriou N">N. Escriou</name></author><author><name sortKey="Callendret, B" uniqKey="Callendret B">B. Callendret</name></author><author><name sortKey="Lorin, V" uniqKey="Lorin V">V. Lorin</name></author><author><name sortKey="Combredet, C" uniqKey="Combredet C">C. Combredet</name></author><author><name sortKey="Marianneau, P" uniqKey="Marianneau P">P. Marianneau</name></author><author><name sortKey="Fevrier, M" uniqKey="Fevrier M">M. Fevrier</name></author><author><name sortKey="Tangy, F" uniqKey="Tangy F">F. Tangy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liniger, M" uniqKey="Liniger M">M. Liniger</name></author><author><name sortKey="Zuniga, A" uniqKey="Zuniga A">A. Zuniga</name></author><author><name sortKey="Tamin, A" uniqKey="Tamin A">A. Tamin</name></author><author><name sortKey="Azzouz Morin, T N" uniqKey="Azzouz Morin T">T.N. Azzouz-Morin</name></author><author><name sortKey="Knuchel, M" uniqKey="Knuchel M">M. Knuchel</name></author><author><name sortKey="Marty, R R" uniqKey="Marty R">R.R. Marty</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kapadia, S U" uniqKey="Kapadia S">S.U. Kapadia</name></author><author><name sortKey="Simon, I D" uniqKey="Simon I">I.D. Simon</name></author><author><name sortKey="Rose, J K" uniqKey="Rose J">J.K. Rose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deming, D" uniqKey="Deming D">D. Deming</name></author><author><name sortKey="Sheahan, T" uniqKey="Sheahan T">T. Sheahan</name></author><author><name sortKey="Heise, M" uniqKey="Heise M">M. Heise</name></author><author><name sortKey="Yount, B" uniqKey="Yount B">B. Yount</name></author><author><name sortKey="Davis, N" uniqKey="Davis N">N. Davis</name></author><author><name sortKey="Sims, A" uniqKey="Sims A">A. Sims</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yasui, F" uniqKey="Yasui F">F. Yasui</name></author><author><name sortKey="Kai, C" uniqKey="Kai C">C. Kai</name></author><author><name sortKey="Kitabatake, M" uniqKey="Kitabatake M">M. Kitabatake</name></author><author><name sortKey="Inoue, S" uniqKey="Inoue S">S. Inoue</name></author><author><name sortKey="Yoneda, M" uniqKey="Yoneda M">M. Yoneda</name></author><author><name sortKey="Yokochi, S" uniqKey="Yokochi S">S. Yokochi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L. Du</name></author><author><name sortKey="Zhao, G" uniqKey="Zhao G">G. Zhao</name></author><author><name sortKey="Chan, C C" uniqKey="Chan C">C.C. Chan</name></author><author><name sortKey="Sun, S" uniqKey="Sun S">S. Sun</name></author><author><name sortKey="Chen, M" uniqKey="Chen M">M. Chen</name></author><author><name sortKey="Liu, Z" uniqKey="Liu Z">Z. Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, E" uniqKey="Kim E">E. Kim</name></author><author><name sortKey="Okada, K" uniqKey="Okada K">K. Okada</name></author><author><name sortKey="Kenniston, T" uniqKey="Kenniston T">T. Kenniston</name></author><author><name sortKey="Raj, V S" uniqKey="Raj V">V.S. Raj</name></author><author><name sortKey="Alhajri, M M" uniqKey="Alhajri M">M.M. AlHajri</name></author><author><name sortKey="Farag, E A" uniqKey="Farag E">E.A. Farag</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Volz, A" uniqKey="Volz A">A. Volz</name></author><author><name sortKey="Kupke, A" uniqKey="Kupke A">A. Kupke</name></author><author><name sortKey="Song, F" uniqKey="Song F">F. Song</name></author><author><name sortKey="Jany, S" uniqKey="Jany S">S. Jany</name></author><author><name sortKey="Fux, R" uniqKey="Fux R">R. Fux</name></author><author><name sortKey="Shams Eldin, H" uniqKey="Shams Eldin H">H. Shams-Eldin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Malczyk, A H" uniqKey="Malczyk A">A.H. Malczyk</name></author><author><name sortKey="Kupke, A" uniqKey="Kupke A">A. Kupke</name></author><author><name sortKey="Prufer, S" uniqKey="Prufer S">S. Prufer</name></author><author><name sortKey="Scheuplein, V A" uniqKey="Scheuplein V">V.A. Scheuplein</name></author><author><name sortKey="Hutzler, S" uniqKey="Hutzler S">S. Hutzler</name></author><author><name sortKey="Kreuz, D" uniqKey="Kreuz D">D. Kreuz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muthumani, K" uniqKey="Muthumani K">K. Muthumani</name></author><author><name sortKey="Falzarano, D" uniqKey="Falzarano D">D. Falzarano</name></author><author><name sortKey="Reuschel, E L" uniqKey="Reuschel E">E.L. Reuschel</name></author><author><name sortKey="Tingey, C" uniqKey="Tingey C">C. Tingey</name></author><author><name sortKey="Flingai, S" uniqKey="Flingai S">S. Flingai</name></author><author><name sortKey="Villarreal, D O" uniqKey="Villarreal D">D.O. Villarreal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lan, J" uniqKey="Lan J">J. Lan</name></author><author><name sortKey="Yao, Y" uniqKey="Yao Y">Y. Yao</name></author><author><name sortKey="Deng, Y" uniqKey="Deng Y">Y. Deng</name></author><author><name sortKey="Chen, H" uniqKey="Chen H">H. Chen</name></author><author><name sortKey="Lu, G" uniqKey="Lu G">G. Lu</name></author><author><name sortKey="Wang, W" uniqKey="Wang W">W. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, N" uniqKey="Zhang N">N. Zhang</name></author><author><name sortKey="Tang, J" uniqKey="Tang J">J. Tang</name></author><author><name sortKey="Lu, L" uniqKey="Lu L">L. Lu</name></author><author><name sortKey="Jiang, S" uniqKey="Jiang S">S. Jiang</name></author><author><name sortKey="Du, L" uniqKey="Du L">L. Du</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haagmans, B L" uniqKey="Haagmans B">B.L. Haagmans</name></author><author><name sortKey="Van Den Brand, J M" uniqKey="Van Den Brand J">J.M. van den Brand</name></author><author><name sortKey="Raj, V S" uniqKey="Raj V">V.S. Raj</name></author><author><name sortKey="Volz, A" uniqKey="Volz A">A. Volz</name></author><author><name sortKey="Wohlsein, P" uniqKey="Wohlsein P">P. Wohlsein</name></author><author><name sortKey="Smits, S L" uniqKey="Smits S">S.L. Smits</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ge, X Y" uniqKey="Ge X">X.Y. Ge</name></author><author><name sortKey="Li, J L" uniqKey="Li J">J.L. Li</name></author><author><name sortKey="Yang, X L" uniqKey="Yang X">X.L. Yang</name></author><author><name sortKey="Chmura, A A" uniqKey="Chmura A">A.A. Chmura</name></author><author><name sortKey="Zhu, G" uniqKey="Zhu G">G. Zhu</name></author><author><name sortKey="Epstein, J H" uniqKey="Epstein J">J.H. Epstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Menachery, V D" uniqKey="Menachery V">V.D. Menachery</name></author><author><name sortKey="Yount, B L" uniqKey="Yount B">B.L. Yount</name></author><author><name sortKey="Debbink, K" uniqKey="Debbink K">K. Debbink</name></author><author><name sortKey="Agnihothram, S" uniqKey="Agnihothram S">S. Agnihothram</name></author><author><name sortKey="Gralinski, L E" uniqKey="Gralinski L">L.E. Gralinski</name></author><author><name sortKey="Plante, J A" uniqKey="Plante J">J.A. Plante</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Falzarano, D" uniqKey="Falzarano D">D. Falzarano</name></author><author><name sortKey="De Wit, E" uniqKey="De Wit E">E. de Wit</name></author><author><name sortKey="Feldmann, F" uniqKey="Feldmann F">F. Feldmann</name></author><author><name sortKey="Rasmussen, A L" uniqKey="Rasmussen A">A.L. Rasmussen</name></author><author><name sortKey="Okumura, A" uniqKey="Okumura A">A. Okumura</name></author><author><name sortKey="Peng, X" uniqKey="Peng X">X. Peng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Johnson, R F" uniqKey="Johnson R">R.F. Johnson</name></author><author><name sortKey="Via, L E" uniqKey="Via L">L.E. Via</name></author><author><name sortKey="Kumar, M R" uniqKey="Kumar M">M.R. Kumar</name></author><author><name sortKey="Cornish, J P" uniqKey="Cornish J">J.P. Cornish</name></author><author><name sortKey="Yellayi, S" uniqKey="Yellayi S">S. Yellayi</name></author><author><name sortKey="Huzella, L" uniqKey="Huzella L">L. Huzella</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Infect. Dis</journal-id><journal-title-group><journal-title>International Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1201-9712</issn><issn pub-type="epub">1878-3511</issn><publisher><publisher-name>The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27062985</article-id><article-id pub-id-type="pmc">4969153</article-id><article-id pub-id-type="publisher-id">S1201-9712(16)31021-9</article-id><article-id pub-id-type="doi">10.1016/j.ijid.2016.04.008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Middle East respiratory syndrome vaccines</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Perlman</surname><given-names>Stanley</given-names></name><email>Stanley-perlman@uiowa.edu</email><xref rid="cor0005" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Vijay</surname><given-names>Rahul</given-names></name></contrib></contrib-group><aff id="aff0005">Department of Microbiology, BSB 3-712, University of Iowa, 51 Newton Road, Iowa City, IA 52242, USA</aff><author-notes><corresp id="cor0005"><label>⁎</label>Corresponding author. Tel.: +1 319 335 8549; fax: +1 319 335 9006. <email>Stanley-perlman@uiowa.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>7</day><month>4</month><year>2016</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>7</day><month>4</month><year>2016</year></pub-date><volume>47</volume><fpage>23</fpage><lpage>28</lpage><history><date date-type="received"><day>1</day><month>1</month><year>2016</year></date><date date-type="rev-recd"><day>31</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>3</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 The Authors</copyright-statement><copyright-year>2016</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0005"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>•</label><p id="par0005">Middle East respiratory syndrome (MERS), caused by a novel coronavirus, is a highly lethal respiratory disease.</p></list-item><list-item id="lsti0010"><label>•</label><p id="par0010">No vaccines or antiviral therapies are available.</p></list-item><list-item id="lsti0015"><label>•</label><p id="par0015">Camels are widely infected and may be good targets for vaccination.</p></list-item><list-item id="lsti0020"><label>•</label><p id="par0020">MERS monoclonal antibodies and human convalescent sera may be useful for prophylaxis and treatment.</p></list-item><list-item id="lsti0025"><label>•</label><p id="par0025">Active immunization strategies, based on the severe acute respiratory syndrome (SARS) experience, are under development.</p></list-item></list></p></abstract><abstract id="abs0010"><title>Summary</title><p>The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected over 1600 individuals with nearly 600 deaths since it was first identified in human populations in 2012. No antiviral therapies or vaccines are available for its treatment or prophylaxis. Approaches to the development of MERS vaccines are discussed herein, including a summary of previous efforts to develop vaccines useful against human and non-human coronaviruses. A striking feature of MERS is the important role that camels have in transmission. Camel vaccination may be a novel approach to preventing human infection.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Middle East respiratory syndrome</kwd><kwd>Vaccines</kwd><kwd>Coronavirus</kwd><kwd>Severe acute respiratory syndrome</kwd><kwd>Human respiratory disease</kwd></kwd-group></article-meta><notes><p id="misc0005"><bold>Corresponding Editor:</bold> Eskild Petersen, Aarhus, Denmark.</p></notes></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0030">Middle East respiratory syndrome (MERS), caused by a novel coronavirus (MERS-CoV), was first identified in 2012 in patients with severe respiratory disease in Jordan and Saudi Arabia.<xref rid="bib0405" ref-type="bibr"><sup>1</sup></xref> Since its discovery, approximately 1600 cases have been reported, amounting to about 40 cases per month. While this number is low, the worrisome features of the disease are its propensity to cause severe disease in patients with underlying conditions, including diabetes, renal disease, lung disease, or an immunocompromised state, and its apparent ability to readily spread within hospital settings.<xref rid="bib0410" ref-type="bibr"><sup>2</sup></xref> In addition, MERS-CoV has been identified in camel populations throughout the Arabian Peninsula and Africa,<xref rid="bib0415" ref-type="bibr">3</xref>, <xref rid="bib0420" ref-type="bibr">4</xref>, <xref rid="bib0425" ref-type="bibr">5</xref> and epidemiological evidence suggests that it is periodically introduced into human populations.<xref rid="bib0430" ref-type="bibr"><sup>6</sup></xref> Further, coronaviruses have a well-described propensity to mutate and recombine.<xref rid="bib0435" ref-type="bibr"><sup>7</sup></xref> Consistent with this propensity, the genomic sequence of MERS-CoV has changed since it first entered human populations in 2012, but these changes have not enhanced the ability to effect human-to-human transmission.<xref rid="bib0440" ref-type="bibr"><sup>8</sup></xref> This lack of increased transmissibility is encouraging, but, on the other hand, the continued introduction into human populations from infected camels coupled with coronavirus mutability means that measures to prevent infection are important to develop anticipatorily.</p><p id="par0035">Following the demonstration of the key role of hospitals in secondary spread,<xref rid="bib0445" ref-type="bibr">9</xref>, <xref rid="bib0450" ref-type="bibr">10</xref> efforts were made to introduce careful infection control measures into affected hospitals. These appear to have been effective in reducing virus transmission and greatly decreasing the number of MERS cases. However, these measures do not affect the acquisition of primary cases of MERS, which likely occur either directly or indirectly from camels. These primary cases are the source for subsequent hospital outbreaks, so preventing transmission from camels or within the community might be the best way to provide subsequent secondary cases and hospital spread.</p><p id="par0040">In addition to the appropriate infection control measures, virus transmission would be most effectively prevented by a combination of rapid and efficient diagnosis, treatment with antiviral therapy to decrease virus loads, and prophylactic treatment with an intervention that prevents infection or at least disease manifestations. Most often, the latter approach involves passive or active immunization, which will be discussed in this review. Efforts to prevent MERS by immunization are based in part on the extensive information gained from studies of coronavirus vaccines used to prevent infections in domesticated and companion animals. Additionally, a key piece of information required for the rational design of vaccines is knowledge of a protective immune response. Immune responses to some non-human coronaviruses have been characterized and these responses are also described below.</p></sec><sec id="sec0010"><label>2</label><title>Protective immune response in animals experimentally infected, or patients naturally or experimentally infected with coronaviruses</title><p id="par0045">In general, protective immune responses to coronaviruses involve a combination of virus-specific antibody and T-cell responses.<xref rid="bib0455" ref-type="bibr"><sup>11</sup></xref> The neutralizing antibody response is primarily directed against the surface (S) protein, responsible for binding to the host cell receptor. The N terminal S1 fragment of the S protein binds to the host cell receptor, elicits neutralizing antibody, and perhaps not surprisingly, is also the part of the virus that is most variable between isolates.<xref rid="bib0460" ref-type="bibr"><sup>12</sup></xref> This variability explains why neutralizing antibodies are generally virus strain-specific and do not provide cross-reactive protection against even closely related coronaviruses.<xref rid="bib0465" ref-type="bibr"><sup>13</sup></xref> On the other hand, coronavirus-specific CD8 and CD4 T-cells recognize epitopes from across the genome, some of which are in conserved proteins, which do not readily undergo mutation.</p><p id="par0050">Prior to the onset of severe acute respiratory syndrome (SARS) and MERS, many studies on protective immune responses used mice infected with the murine coronavirus, mouse hepatitis virus (MHV). These studies showed that virus clearance from infected mice required the development of an effective T-cell response. Both CD4 and CD8 T-cells were required for optimal kinetics of clearance.<xref rid="bib0470" ref-type="bibr"><sup>14</sup></xref> The studies also showed that the T-cell response could be immunopathological.<xref rid="bib0470" ref-type="bibr">14</xref>, <xref rid="bib0475" ref-type="bibr">15</xref>, <xref rid="bib0480" ref-type="bibr">16</xref> Thus when irradiated mice or mice lacking T- and B-cells were infected with a strain of MHV that causes demyelination, the mice developed minimal clinical disease and showed no evidence of demyelination. However, within a few days of receiving virus-specific T-cells, severe myelin destruction occurred, along with hind limb paralysis. Neutralizing antibodies were also important in immune protection, serving at least two roles. First, in the absence of neutralizing antibody, MHV was cleared to very low levels by T-cells, but later recrudesced, resulting in lethal disease.<xref rid="bib0485" ref-type="bibr"><sup>17</sup></xref> Second, virus-specific antibodies were most important for protecting mice against further challenge. Of note, immune protection was long-lived in immunocompetent mice that survived experimental infection with MHV, possibly because the infection was systemic, involving the central nervous system, or in some cases, the liver.</p><p id="par0055">In marked contrast, coronaviruses that are primarily mucosal induce short-lived protection. This is most evident in studies of patients or human volunteers infected with respiratory coronaviruses such as HCoV-229E or HCoV-OC43.<xref rid="bib0490" ref-type="bibr">18</xref>, <xref rid="bib0495" ref-type="bibr">19</xref> These viruses generally cause mild upper respiratory tract disease and only rarely cause severe disease. In human volunteer studies, the presence of pre-existing anti-HCoV-OC43 or HCoV-229E antibodies did not provide protection against experimental challenge with the same virus, in terms of clinical disease or virus titers. Similarly, experimental challenge provided only partial protection against subsequent re-challenge and this protection waned over several months. In these studies, systemic antibodies were generally measured, so less is known about the levels of IgA, which are likely most important for protection against viruses that remain confined to the upper respiratory tract.</p><p id="par0060">From these data, one might predict that infection with MERS-CoV or SARS-CoV would result in a long-lived protective response, since SARS-CoV and MERS-CoV cause severe respiratory illness based in the lungs, and SARS-CoV (and perhaps MERS-CoV) causes a systemic infection.<xref rid="bib0500" ref-type="bibr"><sup>20</sup></xref> However, this may not be the case. While only a few SARS survivors have been followed longitudinally, anti-SARS-CoV antibody titers were not detectable after 6 years.<xref rid="bib0505" ref-type="bibr"><sup>21</sup></xref> Longitudinal studies of T-cell responses in these patients are even fewer in number, but T-cell responses were detected at low levels in some survivors.<xref rid="bib0505" ref-type="bibr">21</xref>, <xref rid="bib0510" ref-type="bibr">22</xref>, <xref rid="bib0515" ref-type="bibr">23</xref>, <xref rid="bib0520" ref-type="bibr">24</xref> While these data suggest that coronavirus-specific T-cells are more likely to persist than B-cells, it is still possible that there are sufficient numbers of residual memory T- and B-cells to protect patients from infection or severe disease on rechallenge.</p></sec><sec id="sec0015"><label>3</label><title>Previous studies of coronavirus-vaccinated domesticated and companion animals</title><p id="par0065">Prior to the outbreak of SARS, coronaviruses were considered most important as causes of infections of domesticated and companion animals. Vaccines to prevent several of these diseases were developed over the years, but none were very successful in preventing disease. Infectious bronchitis virus (IBV) is an economically important infection of young chickens, causing bronchitis as well as renal disease (reviewed by Cavanagh<xref rid="bib0525" ref-type="bibr"><sup>25</sup></xref>). Live attenuated vaccines were developed, which were efficacious in providing short-term protection to challenge with homologous but not heterologous IBV strains. Levels of circulating IBV did not diminish substantially because many strains of IBV co-circulate in chicken populations. Recombination between the vaccine and circulating strains resulted in the emergence of novel strains of IBV.</p><p id="par0070">Live attenuated vaccines were also developed for a swine coronavirus, transmissible gastroenteritis virus (TGEV), which causes fatal diarrhea with associated high mortality in very young pigs.<xref rid="bib0530" ref-type="bibr"><sup>26</sup></xref> These vaccines were administered to pregnant sows but did not protect piglets to a great extent; the use of virulent virus in sows was more successful in protecting baby animals from lethal disease. Remarkably, however, a deletion variant of TGEV, porcine respiratory coronavirus (PRC), appeared in swine populations in North America and Eurasia.<xref rid="bib0535" ref-type="bibr"><sup>27</sup></xref> PRC caused only a mild respiratory disease, but induced an immune response that was cross-reactive and protective against TGEV, resulting in the disappearance of TGEV from most locales.</p><p id="par0075">Finally, feline infectious peritonitis virus (FIPV) causes a lethal granulomatous disease in domestic cats and other felines, with wet (pyogranulomatous, effusive) and dry (classic granulomatous) forms.<xref rid="bib0540" ref-type="bibr"><sup>28</sup></xref> FIP is uncommon and most often occurs in animals chronically infected with feline coronavirus (FCV), which mutates during the course of persistence. A vaccinia virus-based vaccine expressing the FIPV surface (S) glycoprotein was developed, and was shown to induce high levels of anti-FIPV neutralizing antibody.<xref rid="bib0545" ref-type="bibr"><sup>29</sup></xref> However, this anti-S antibody was not protective against challenge with virulent FIPV. Rather, it induced an antibody-dependent accelerated and enhanced disease after challenge. Of note, antibody-dependent enhancement has never been observed in naturally infected felines, but the possibility that it might develop has been a concern as vaccines for SARS-CoV and MERS-CoV are developed.<xref rid="bib0550" ref-type="bibr"><sup>30</sup></xref></p></sec><sec id="sec0020"><label>4</label><title>Development of anti-SARS-CoV and MERS-CoV vaccines</title><p id="par0080">Vaccines useful for preventing SARS or MERS have been developed, based on information learned from the studies described above (<xref rid="tbl0005" ref-type="table">Table 1</xref>). Because both SARS and MERS tend to spread extensively within hospital settings, initial efforts were directed at developed reagents that could be used for passive immunization; more recent efforts have focused on methods useful for active immunization. In this section, vaccines targeting SARS-CoV are described first, since many of the approaches used in developing MERS vaccines were initially investigated in the context of SARS.<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Middle East respiratory syndrome coronavirus vaccines</p></caption><alt-text id="at1">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Vaccine</th><th align="left">Target</th><th align="left">Use</th><th align="left">Advantages</th><th align="left">Problems</th></tr></thead><tbody><tr><td align="left">Anti-MERS-CoV monoclonal antibodies</td><td align="left">Surface (S) glycoprotein</td><td align="left">Passive immunization;<break></break>prophylaxis or treatment at early times p.i.</td><td align="left">High titer preparations; can be produced in large amounts</td><td align="left">Short half-life; needs to be re-administered for continued efficacy</td></tr><tr><td align="left">Human polyclonal anti-MERS-CoV antibodies</td><td align="left">Virus structural proteins</td><td align="left">Passive immunization; treatment at early times p.i.</td><td align="left">Polyclonal antibody so antibody escape unlikely; human antibody</td><td align="left">Short half-life; needs to be re-administered for continued efficacy; few MERS survivors available as donors</td></tr><tr><td align="left">Inactivated virion vaccines</td><td align="left">Virus structural proteins; anti-S neutralizing antibodies most important</td><td align="left">Active immunization</td><td align="left">High titer antibody to S protein</td><td align="left">Response may not be long term; on challenge may induce immunopathological disease; may be ineffective in aged populations</td></tr><tr><td align="left">Live attenuated vaccines (e.g., viruses deleted in envelope (E) protein; viruses with reduced fidelity (mutated in nsp14)</td><td align="left">Mostly virus structural proteins</td><td align="left">Active immunization</td><td align="left">Generally safe; induce antibody and T-cell responses; long-term immunity</td><td align="left">May not be safe in immunocompromised patients; may regain virulence by reversion or recombination with circulating CoV</td></tr><tr><td align="left">Viral vector (attenuated) vaccines: poxvirus, AAV adenovirus, parainfluenza virus, rabies virus, measles virus, VSV</td><td align="left">S protein</td><td align="left">Active immunization</td><td align="left">Safe; non-replicating; induce antibody and T-cell responses</td><td align="left">Long-term immunity, but not as long as live attenuated vaccines</td></tr><tr><td align="left">Replicon particles (e.g., VEEV or VSV-based)</td><td align="left">S protein or any viral protein</td><td align="left">Active immunization</td><td align="left">Safe; non-replicating; induce antibody and T-cell responses; useful for mucosal immunity</td><td align="left">Production is complex</td></tr><tr><td align="left">Subunit vaccines (e.g. RBD of S protein)</td><td align="left">Generally S protein</td><td align="left">Active immunization</td><td align="left">Safe; non-replicating; induce high antibody titers; may also induce T-cell responses</td><td align="left">Duration of response not known</td></tr><tr><td align="left">DNA vaccines</td><td align="left">Generally S protein</td><td align="left">Active immunization</td><td align="left">Safe; induce high antibody titers and T-cell responses</td><td align="left">Immunogenicity variable; may induce<break></break>anti-DNA immune response</td></tr></tbody></table><table-wrap-foot><fn><p>MERS-CoV, Middle East respiratory syndrome coronavirus; p.i., post infection; AAV, adeno-associated virus; VSV, vesicular stomatitis virus; VEEV, Venezuelan equine encephalitis virus; RBD, receptor binding domain.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec0025"><label>4.1</label><title>Passive immunization</title><sec id="sec0030"><label>4.1.1</label><title>SARS</title><p id="par0085">Monoclonal antibodies (mAb) with neutralizing activity against SARS-CoV have been isolated from non-immune human volunteers.<xref rid="bib0555" ref-type="bibr">31</xref>, <xref rid="bib0560" ref-type="bibr">32</xref> The advantage of this approach is that protective antibodies can be isolated, cloned, and propagated without the need to obtain patient specimens. Other approaches have included identifying and cloning memory B-cells obtained from SARS survivors and amplifying those that produce the most potently neutralizing antibodies.<xref rid="bib0565" ref-type="bibr"><sup>33</sup></xref> In all of these vaccines, neutralizing antibodies have been directed against the S protein. Stockpiled anti-SARS-CoV antibodies would be especially useful in the healthcare or family setting to provide prophylaxis or treatment if administered very soon after exposure.</p><p id="par0090">Convalescent sera from SARS survivors have also been used to treat patients.<xref rid="bib0570" ref-type="bibr">34</xref>, <xref rid="bib0575" ref-type="bibr">35</xref> Efficacy was not demonstrated, but this may well have reflected the administration of sera after disease had already developed; the clinical presentation of SARS is non-specific, making it difficult to identify infected patients at an early time during the disease course. Convalescent sera would be most useful in an outbreak setting in which a large fraction of patients with respiratory disease might be expected to have SARS and therefore benefit from treatment.</p></sec><sec id="sec0035"><label>4.1.2</label><title>MERS</title><p id="par0095">Similar strategies have been used to isolate and amplify antibodies with MERS-CoV neutralizing activity. Initial reports described the isolation of neutralizing antibodies from naïve human antibody populations using phage display and yeast display.<xref rid="bib0580" ref-type="bibr">36</xref>, <xref rid="bib0585" ref-type="bibr">37</xref>, <xref rid="bib0590" ref-type="bibr">38</xref> In another approach, a mAb with high avidity for the MERS-CoV S proteins was isolated from B-cells harvested from a MERS patient after cloning into a mammalian expression system.<xref rid="bib0595" ref-type="bibr"><sup>39</sup></xref> This antibody was shown to efficiently accelerate the kinetics of virus clearance and diminish pathological changes in mice infected with MERS-CoV. Mice are not naturally infectable by MERS-CoV because the virus cannot use the mouse MERS-CoV receptor (dipeptidyl peptidase, DPP4) to enter cells. In this instance, mice were sensitized to MERS-CoV by prior transduction with an adenovirus engineered to express human DPP4 (hDPP4).<xref rid="bib0600" ref-type="bibr"><sup>40</sup></xref> In another approach, fully human antibodies with MERS-CoV neutralizing activity were developed using mice that expressed human antibody heavy and κ light chains. In this study, efficacy was examined in mice that had been engineered to express hDPP4 in lieu of mDPP4 (‘knock-in’, KI mice).<xref rid="bib0605" ref-type="bibr"><sup>41</sup></xref> The humanized anti-S mAbs accelerated virus clearance and reduced pathological changes in mouse lungs.</p><p id="par0100">The use of convalescent sera from MERS survivors has been proposed based on studies of SARS patients.<xref rid="bib0575" ref-type="bibr"><sup>35</sup></xref> However, the limited availability of convalescent sera may make its use infeasible. Camels are considered the primary reservoir for human MERS and appear to be periodically reinfected by the virus. Consequently, MERS-CoV antibody titers are elevated. The administration of sera from previously infected camels to MERS-CoV challenged hDPP4-transduced mice was shown to accelerate MERS-CoV clearance and reduce pathological changes in the lungs.<xref rid="bib0610" ref-type="bibr"><sup>42</sup></xref></p></sec></sec><sec id="sec0040"><label>4.2</label><title>Active immunization</title><sec id="sec0045"><label>4.2.1</label><title>SARS</title><p id="par0105">Most vaccines have been directed at developing anti-S neutralizing antibody responses. Vaccines have included inactivated whole virus vaccines, live attenuated virus DNA vaccines, viral vector vaccines, subunit vaccines, and DNA vaccines. DNA vaccines were shown to induce anti-S antibodies in mice and were later shown to induce virus-specific neutralizing antibody and T-cell responses in a phase I human trial.<xref rid="bib0615" ref-type="bibr">43</xref>, <xref rid="bib0620" ref-type="bibr">44</xref> Inactivated SARS-CoV vaccines were developed and tested in experimentally infected animals as well as in phase I human trials.<xref rid="bib0625" ref-type="bibr"><sup>45</sup></xref> These vaccines induced strong anti-S antibody responses if administered with adjuvants such as β-propiolactone or formalin,<xref rid="bib0630" ref-type="bibr"><sup>46</sup></xref> but subsequent studies suggested that they also induced eosinophilia and other signs of immunopathological disease upon challenge.<xref rid="bib0635" ref-type="bibr">47</xref>, <xref rid="bib0640" ref-type="bibr">48</xref> Human phase I trials testing this reagent were halted based on these putative immunopathological changes. Live attenuated vaccines offer the best opportunity for developing both antibody and T-cell responses without eosinophilic infiltration or other manifestations of immunopathological disease in the lungs.</p><p id="par0110">Engineering of live attenuated vaccines has been facilitated by the development of reverse genetics systems for SARS-CoV, as well as other coronaviruses, including MERS-CoV.<xref rid="bib0645" ref-type="bibr">49</xref>, <xref rid="bib0650" ref-type="bibr">50</xref> Using one of these methodologies, viruses deleted in the small envelope (E) protein were developed. These viruses were shown to be attenuated and to induce protective humoral and cell-based immune responses in hamsters and mice after SARS-CoV challenge.<xref rid="bib0655" ref-type="bibr">51</xref>, <xref rid="bib0660" ref-type="bibr">52</xref>, <xref rid="bib0665" ref-type="bibr">53</xref> Further investigations showed that this vaccine was not genetically stable, with partial duplication of the transmembrane (M) protein detected upon repeated passage. Remarkably, this genetic change resulted in re-acquisition of a PDZ binding motif (PBM) important for protein–protein interactions.<xref rid="bib0670" ref-type="bibr"><sup>54</sup></xref> If the E protein was only partially deleted so that the PBM was retained, the virus was genetically stable, attenuated, and immunogenic. In another approach, virus mutated at the catalytic site of a protein critical for genome fidelity during replication (nsp14) resulted in an attenuated virus that did not revert upon repeated passage in cells and mice, was safe even in highly immunocompromised mice, and induced a strong anti-S antibody response.<xref rid="bib0675" ref-type="bibr"><sup>55</sup></xref> Further efforts to maximize the biosafety of these live attenuated vaccines include the introduction of additional mutations into non-essential proteins or into non-coding regions of the genomic RNA, which minimize the likelihood of a virulent virus arising after recombination with circulating coronavirus strains.<xref rid="bib0680" ref-type="bibr">56</xref>, <xref rid="bib0685" ref-type="bibr">57</xref></p><p id="par0115">Attenuated poxvirus,<xref rid="bib0690" ref-type="bibr"><sup>58</sup></xref> adenovirus,<xref rid="bib0695" ref-type="bibr">59</xref>, <xref rid="bib0700" ref-type="bibr">60</xref> adeno-associated virus,<xref rid="bib0705" ref-type="bibr"><sup>61</sup></xref> parainfluenza virus,<xref rid="bib0710" ref-type="bibr"><sup>62</sup></xref> rabies virus,<xref rid="bib0715" ref-type="bibr"><sup>63</sup></xref> measles virus,<xref rid="bib0720" ref-type="bibr">64</xref>, <xref rid="bib0725" ref-type="bibr">65</xref> and vesicular stomatitis virus<xref rid="bib0730" ref-type="bibr"><sup>66</sup></xref> vectors expressing either full-length SARS-CoV S protein or the S1 extracellular domain have been engineered. These vaccines also induced high levels of SARS-CoV neutralizing antibody titers. Venezuelan equine encephalitis virus replicons (VRPs) expressing viral proteins have been shown to induce potent T-cell and antibody responses and to act as self-adjuvants. A major advantage of VRPs is that since they are non-replicating, they are not infectious and will not recombine with circulating CoV to generate new variants. VRPs expressing the S or nucleocapsid (N) protein, like other vaccines, were found to be less effective in senescent mice and VRP-N was reported to induce immunopathological disease.<xref rid="bib0735" ref-type="bibr"><sup>67</sup></xref> Similar immunopathology was observed after SARS-CoV challenge of mice previously immunized with the N protein.<xref rid="bib0740" ref-type="bibr"><sup>68</sup></xref></p><p id="par0120">Potent neutralizing antibody responses have also been induced in mice immunized with constructs expressing the receptor binding domain, the part of the SARS-CoV protein that actually binds to the receptor (angiotensin-converting enzyme 2, ACE2) on target cells.<xref rid="bib0745" ref-type="bibr"><sup>69</sup></xref> These subunit vaccines exhibit high safety profiles and have minimal side effects in addition to being immunogenic.</p></sec><sec id="sec0050"><label>4.2.2</label><title>MERS</title><p id="par0125">Many of the approaches described above have been used to develop MERS vaccines. Recombinant adenoviruses,<xref rid="bib0750" ref-type="bibr"><sup>70</sup></xref> poxviruses,<xref rid="bib0755" ref-type="bibr"><sup>71</sup></xref> and measles virus<xref rid="bib0760" ref-type="bibr"><sup>72</sup></xref> expressing full-length S protein or the extracellular S1 domain have been engineered and tested in experimentally infected animals. All were able to induce an anti-S protein antibody response. Although not examined, it is likely that some or all of them also induced CD8 and CD4 T-cell responses. Live attenuated MERS-CoV vaccines have not yet been described, although it is likely, based on SARS-CoV data,<xref rid="bib0675" ref-type="bibr"><sup>55</sup></xref> that virus mutated in the catalytic site of the exonuclease of nsp14 would be an excellent vaccine candidate.</p><p id="par0130">DNA vaccines that induce MERS-CoV-specific antibody and T-cell responses have been described and shown to be efficacious in non-human primates.<xref rid="bib0765" ref-type="bibr"><sup>73</sup></xref> Vaccines expressing the MERS-CoV receptor binding domain (RBD) induced potent neutralizing antibodies in mice and neutralizing antibodies and T-cell responses in non-human primates.<xref rid="bib0770" ref-type="bibr">74</xref>, <xref rid="bib0775" ref-type="bibr">75</xref> Vaccination resulted in accelerated virus clearance and diminished pathological changes, but did not prevent infection.</p><p id="par0135">While vaccine development usually targets human populations, MERS-CoV infects a much greater number and higher percentage of camels than humans in the Arabian Peninsula and in Africa. Thus camel vaccination is an approach to decrease the amount of circulating virus and also diminish the amount of virus secreted by infected animals. A recent study showed that this approach is feasible. Camels were immunized with an orthopoxvirus vector (modified vaccinia virus Ankara, MVA) expressing the S protein.<xref rid="bib0780" ref-type="bibr"><sup>76</sup></xref> After challenge with MERS-CoV at 3 weeks after boosting, clinical signs (rhinitis) and infectious virus titers in the upper respiratory tract, the main site of replication in the camel, were diminished in immunized compared to control animals.</p></sec></sec></sec><sec id="sec0055"><label>5</label><title>Conclusions and future directions</title><p id="par0140">While several promising MERS vaccine candidates are under development, several issues need to be resolved. First, an important consideration is whether humans or, alternatively, camels should be vaccinated. Humans but not camels develop severe respiratory disease, but only a relatively small total number of infected individuals have been identified and many of these have had co-morbidities, which would impair vaccine responsiveness. In the absence of a greater disease burden in human populations, it seems unlikely that human vaccination would ever be economically viable. On the other hand, a high percentage of camels are infected with MERS-CoV and vaccination reduces virus load, although without inducing sterilizing immunity. The longevity of the camel immune response is not known but may be short, since camels appear to be readily re-infected with MERS-CoV. Further, the large size of camels plus the number of camels potentially requiring immunization would cause logistical problems.</p><p id="par0145">Second, most vaccines induce anti-S neutralizing antibody responses. The receptor binding part of the S protein, the target for most neutralizing antibodies, is the most variable part of the S protein so that antibodies are highly strain-specific. While the S protein of MERS-CoV has not shown evidence of mutations that result in antibody evasion, this is still a possibility because coronaviruses are prone to mutation and recombination. Thus, targeting the S protein may provide protection against MERS-CoV but may not be useful against either a closely related strain or one that evolves in response to immune or other pressure in humans. This possibility was highlighted in a recent study that showed that two bat strains of SARS-like CoV were closely related to human SARS-CoV and used the same ACE2 receptor to enter cells.<xref rid="bib0785" ref-type="bibr">77</xref>, <xref rid="bib0790" ref-type="bibr">78</xref> However, anti-SARS-CoV S antibodies could not neutralize one of these strains.<xref rid="bib0790" ref-type="bibr"><sup>78</sup></xref></p><p id="par0150">Third, T-cell responses in MERS and SARS survivors have not been investigated widely, but these tend to target more conserved regions of the viral genome and will provide protection against strains that differ in the RBD. Analysis of the T-cell response is facilitated by the identification of CD8 or CD4 T-cell epitopes. T-cell epitopes have been identified in some inbred strains of mice,<xref rid="bib0600" ref-type="bibr"><sup>40</sup></xref> but are more difficult to identify in human populations because of inter-individual human leukocyte antigen (HLA) diversity. The extent to which vaccines should be formulated to induce T-cell responses as well as neutralizing antibody responses is not yet resolved.</p><p id="par0155">Fourth, prior to use in humans, vaccines need to be carefully evaluated in experimentally infected animals. No laboratory animal infected with MERS-CoV develops disease with the same pathogenesis as occurs in patients with severe respiratory disease. Marmosets develop severe disease in some laboratory settings but not all.<xref rid="bib0795" ref-type="bibr">79</xref>, <xref rid="bib0800" ref-type="bibr">80</xref> Even if a lethal mouse-adapted MERS-CoV is identified, disease in the mouse and untoward effects of vaccines may not mirror the human infection sufficiently. Better animal models for MERS would facilitate more useful and accurate in vivo vaccine evaluation.</p><p id="par0160">In conclusion, it was learned from the Ebola pandemic that preparedness for epidemic spread of a virus that has never exhibited such spread in the past is critical. So far, there has not been an upsurge in MERS cases during the Hajj or Umrah pilgrimages. Nevertheless, consideration of how to develop tools for passive and active immunization is critical.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0405"><label>1</label><element-citation publication-type="journal" id="sbref0405"><person-group person-group-type="author"><name><surname>Zaki</surname><given-names>A.M.</given-names></name><name><surname>van Boheemen</surname><given-names>S.</given-names></name><name><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N Engl J Med</source><volume>367</volume><year>2012</year><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="bib0410"><label>2</label><element-citation publication-type="journal" id="sbref0410"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Middle East respiratory syndrome</article-title><source>Lancet</source><volume>386</volume><year>2015</year><fpage>995</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">26049252</pub-id></element-citation></ref><ref id="bib0415"><label>3</label><element-citation publication-type="journal" id="sbref0415"><person-group person-group-type="author"><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Jores</surname><given-names>J.</given-names></name><name><surname>Meyer</surname><given-names>B.</given-names></name><name><surname>Younan</surname><given-names>M.</given-names></name><name><surname>Liljander</surname><given-names>A.</given-names></name><name><surname>Said</surname><given-names>M.Y.</given-names></name></person-group><article-title>Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992-2013</article-title><source>Emerg Infect Dis</source><volume>20</volume><year>2014</year><fpage>1319</fpage><lpage>1322</lpage><pub-id pub-id-type="pmid">25075637</pub-id></element-citation></ref><ref id="bib0420"><label>4</label><element-citation publication-type="journal" id="sbref0420"><person-group person-group-type="author"><name><surname>Hemida</surname><given-names>M.G.</given-names></name><name><surname>Chu</surname><given-names>D.K.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name><name><surname>Perera</surname><given-names>R.A.</given-names></name><name><surname>Alhammadi</surname><given-names>M.A.</given-names></name><name><surname>Ng</surname><given-names>H.Y.</given-names></name></person-group><article-title>MERS coronavirus in dromedary camel herd, Saudi Arabia</article-title><source>Emerg Infect Dis</source><volume>20</volume><year>2014</year><fpage>1231</fpage><lpage>1234</lpage><pub-id pub-id-type="pmid">24964193</pub-id></element-citation></ref><ref id="bib0425"><label>5</label><element-citation publication-type="journal" id="sbref0425"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>M.A.</given-names></name><name><surname>Corman</surname><given-names>V.M.</given-names></name><name><surname>Jores</surname><given-names>J.</given-names></name><name><surname>Meyer</surname><given-names>B.</given-names></name><name><surname>Younan</surname><given-names>M.</given-names></name><name><surname>Lijander</surname><given-names>A.</given-names></name></person-group><article-title>MERS coronavirus neutralizing antibodies in camels, Eastern Africa 1983-1997</article-title><source>Emerg Infect Dis</source><volume>20</volume><year>2014</year><fpage>2093</fpage><lpage>2095</lpage><pub-id pub-id-type="pmid">25425139</pub-id></element-citation></ref><ref id="bib0430"><label>6</label><element-citation publication-type="journal" id="sbref0430"><person-group person-group-type="author"><name><surname>Sabir</surname><given-names>J.S.</given-names></name><name><surname>Lam</surname><given-names>T.T.</given-names></name><name><surname>Ahmed</surname><given-names>M.M.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Abo-Aba</surname><given-names>S.E.</given-names></name></person-group><article-title>Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia</article-title><source>Science</source><volume>351</volume><year>2015</year><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">26678874</pub-id></element-citation></ref><ref id="bib0435"><label>7</label><element-citation publication-type="book" id="sbref0435"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>P.S.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><chapter-title><italic>Coronaviridae</italic></chapter-title><person-group person-group-type="editor"><name><surname>Knipe</surname><given-names>D.M.</given-names></name><name><surname>Howley</surname><given-names>P.M.</given-names></name></person-group><series>Fields virology</series><volume>Vol. 1</volume><year>2013</year><publisher-name>Lippincott Williams and Wilkins</publisher-name><publisher-loc>Philadelphia, PA</publisher-loc><fpage>825</fpage><lpage>858</lpage></element-citation></ref><ref id="bib0440"><label>8</label><element-citation publication-type="journal" id="sbref0440"><person-group person-group-type="author"><name><surname>Cotten</surname><given-names>M.</given-names></name><name><surname>Watson</surname><given-names>S.J.</given-names></name><name><surname>Zumla</surname><given-names>A.I.</given-names></name><name><surname>Makhdoom</surname><given-names>H.Q.</given-names></name><name><surname>Palser</surname><given-names>A.L.</given-names></name><name><surname>Ong</surname><given-names>S.H.</given-names></name></person-group><article-title>Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus</article-title><source>MBio</source><volume>5</volume><year>2014</year><fpage>e01062-13</fpage><pub-id pub-id-type="pmid">24549846</pub-id></element-citation></ref><ref id="bib0445"><label>9</label><element-citation publication-type="journal" id="sbref0445"><person-group person-group-type="author"><name><surname>Al-Abdallat</surname><given-names>M.M.</given-names></name><name><surname>Payne</surname><given-names>D.C.</given-names></name><name><surname>Alqasrawi</surname><given-names>S.</given-names></name><name><surname>Rha</surname><given-names>B.</given-names></name><name><surname>Tohme</surname><given-names>R.A.</given-names></name><name><surname>Abedi</surname><given-names>G.R.</given-names></name></person-group><article-title>Hospital-associated outbreak of middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description</article-title><source>Clin Infect Dis</source><volume>59</volume><year>2014</year><fpage>1225</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">24829216</pub-id></element-citation></ref><ref id="bib0450"><label>10</label><element-citation publication-type="journal" id="sbref0450"><person-group person-group-type="author"><name><surname>Oboho</surname><given-names>I.K.</given-names></name><name><surname>Tomczyk</surname><given-names>S.M.</given-names></name><name><surname>Al-Asmari</surname><given-names>A.M.</given-names></name><name><surname>Banjar</surname><given-names>A.A.</given-names></name><name><surname>Al-Mugti</surname><given-names>H.</given-names></name><name><surname>Aloraini</surname><given-names>M.S.</given-names></name></person-group><article-title>2014 MERS-CoV outbreak in Jeddah—a link to health care facilities</article-title><source>N Engl J Med</source><volume>372</volume><year>2015</year><fpage>846</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">25714162</pub-id></element-citation></ref><ref id="bib0455"><label>11</label><element-citation publication-type="journal" id="sbref0455"><person-group person-group-type="author"><name><surname>Bergmann</surname><given-names>C.C.</given-names></name><name><surname>Lane</surname><given-names>T.E.</given-names></name><name><surname>Stohlman</surname><given-names>S.A.</given-names></name></person-group><article-title>Coronavirus infection of the central nervous system: host-virus stand-off</article-title><source>Nat Rev Microbiol</source><volume>4</volume><year>2006</year><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">16415928</pub-id></element-citation></ref><ref id="bib0460"><label>12</label><element-citation publication-type="journal" id="sbref0460"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Zheng</surname><given-names>B.J.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>The spike protein of SARS-CoV—a target for vaccine and therapeutic development</article-title><source>Nat Rev Microbiol</source><volume>7</volume><year>2009</year><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">19198616</pub-id></element-citation></ref><ref id="bib0465"><label>13</label><element-citation publication-type="journal" id="sbref0465"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T.</given-names></name><name><surname>Rockx</surname><given-names>B.</given-names></name><name><surname>Donaldson</surname><given-names>E.</given-names></name><name><surname>Sims</surname><given-names>A.</given-names></name><name><surname>Pickles</surname><given-names>R.</given-names></name><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Baric</surname><given-names>R.</given-names></name></person-group><article-title>Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium</article-title><source>J Virol</source><volume>82</volume><year>2008</year><fpage>2274</fpage><lpage>2285</lpage><pub-id pub-id-type="pmid">18094188</pub-id></element-citation></ref><ref id="bib0470"><label>14</label><element-citation publication-type="journal" id="sbref0470"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>J.S.</given-names></name><name><surname>Stohlman</surname><given-names>S.A.</given-names></name></person-group><article-title>Effective clearance of mouse hepatitis virus from the central nervous system requires both CD4+ and CD8+ T cells</article-title><source>J Virol</source><volume>64</volume><year>1990</year><fpage>4589</fpage><lpage>4592</lpage><pub-id pub-id-type="pmid">2166833</pub-id></element-citation></ref><ref id="bib0475"><label>15</label><element-citation publication-type="journal" id="sbref0475"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Stohlman</surname><given-names>S.A.</given-names></name><name><surname>Fleming</surname><given-names>J.O.</given-names></name></person-group><article-title>Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated</article-title><source>J Neuroimmunol</source><volume>30</volume><year>1990</year><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">2172304</pub-id></element-citation></ref><ref id="bib0480"><label>16</label><element-citation publication-type="journal" id="sbref0480"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G.F.</given-names></name><name><surname>Dandekar</surname><given-names>A.A.</given-names></name><name><surname>Pewe</surname><given-names>L.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination</article-title><source>J Immunol</source><volume>165</volume><year>2000</year><fpage>2278</fpage><lpage>2286</lpage><pub-id pub-id-type="pmid">10925317</pub-id></element-citation></ref><ref id="bib0485"><label>17</label><element-citation publication-type="journal" id="sbref0485"><person-group person-group-type="author"><name><surname>Ramakrishna</surname><given-names>C.</given-names></name><name><surname>Stohlman</surname><given-names>S.A.</given-names></name><name><surname>Atkinson</surname><given-names>R.D.</given-names></name><name><surname>Shlomchik</surname><given-names>M.J.</given-names></name><name><surname>Bergmann</surname><given-names>C.C.</given-names></name></person-group><article-title>Mechanisms of central nervous system viral persistence: the critical role of antibody and B cells</article-title><source>J Immunol</source><volume>168</volume><year>2002</year><fpage>1204</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">11801656</pub-id></element-citation></ref><ref id="bib0490"><label>18</label><element-citation publication-type="journal" id="sbref0490"><person-group person-group-type="author"><name><surname>Bradburne</surname><given-names>A.F.</given-names></name><name><surname>Somerset</surname><given-names>B.A.</given-names></name></person-group><article-title>Coronavirus antibody tires in sera of healthy adults and experimentally infected volunteers</article-title><source>J Hyg (Lond)</source><volume>70</volume><year>1972</year><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">4503867</pub-id></element-citation></ref><ref id="bib0495"><label>19</label><element-citation publication-type="journal" id="sbref0495"><person-group person-group-type="author"><name><surname>Callow</surname><given-names>K.A.</given-names></name><name><surname>Parry</surname><given-names>H.F.</given-names></name><name><surname>Sergeant</surname><given-names>M.</given-names></name><name><surname>Tyrrell</surname><given-names>D.A.</given-names></name></person-group><article-title>The time course of the immune response to experimental coronavirus infection of man</article-title><source>Epidemiol Infect</source><volume>105</volume><year>1990</year><fpage>435</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">2170159</pub-id></element-citation></ref><ref id="bib0500"><label>20</label><element-citation publication-type="journal" id="sbref0500"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name><surname>Stohr</surname><given-names>K.</given-names></name></person-group><article-title>The severe acute respiratory syndrome</article-title><source>N Engl J Med</source><volume>349</volume><year>2003</year><fpage>2431</fpage><lpage>2441</lpage><pub-id pub-id-type="pmid">14681510</pub-id></element-citation></ref><ref id="bib0505"><label>21</label><element-citation publication-type="journal" id="sbref0505"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>F.</given-names></name><name><surname>Quan</surname><given-names>Y.</given-names></name><name><surname>Xin</surname><given-names>Z.T.</given-names></name><name><surname>Wrammert</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>M.J.</given-names></name><name><surname>Lv</surname><given-names>H.</given-names></name></person-group><article-title>Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study</article-title><source>J Immunol</source><volume>186</volume><year>2011</year><fpage>7264</fpage><lpage>7268</lpage><pub-id pub-id-type="pmid">21576510</pub-id></element-citation></ref><ref id="bib0510"><label>22</label><element-citation publication-type="journal" id="sbref0510"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y.Y.</given-names></name><name><surname>Huang</surname><given-names>Z.T.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>M.H.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Koup</surname><given-names>R.A.</given-names></name></person-group><article-title>Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection</article-title><source>Arch Virol</source><volume>154</volume><year>2009</year><fpage>1093</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">19526193</pub-id></element-citation></ref><ref id="bib0515"><label>23</label><element-citation publication-type="journal" id="sbref0515"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>L.T.</given-names></name><name><surname>Wang</surname><given-names>L.Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Z.Q.</given-names></name></person-group><article-title>Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients</article-title><source>Virology</source><volume>351</volume><year>2006</year><fpage>466</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">16690096</pub-id></element-citation></ref><ref id="bib0520"><label>24</label><element-citation publication-type="journal" id="sbref0520"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.T.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>Z.L.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>Z.T.</given-names></name><name><surname>Zhao</surname><given-names>Z.X.</given-names></name></person-group><article-title>Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients</article-title><source>Clin Immunol</source><volume>120</volume><year>2006</year><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">16781892</pub-id></element-citation></ref><ref id="bib0525"><label>25</label><element-citation publication-type="journal" id="sbref0525"><person-group person-group-type="author"><name><surname>Cavanagh</surname><given-names>D.</given-names></name></person-group><article-title>Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus</article-title><source>Avian Pathol</source><volume>32</volume><year>2003</year><fpage>567</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">14676007</pub-id></element-citation></ref><ref id="bib0530"><label>26</label><element-citation publication-type="journal" id="sbref0530"><person-group person-group-type="author"><name><surname>Saif</surname><given-names>L.J.</given-names></name></person-group><article-title>Enteric viral infections of pigs and strategies for induction of mucosal immunity</article-title><source>Adv Vet Med</source><volume>41</volume><year>1999</year><fpage>429</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">9890034</pub-id></element-citation></ref><ref id="bib0535"><label>27</label><element-citation publication-type="journal" id="sbref0535"><person-group person-group-type="author"><name><surname>Schwegmann-Wessels</surname><given-names>C.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name></person-group><article-title>Transmissible gastroenteritis virus infection: a vanishing specter</article-title><source>Dtsch Tierarztl Wochenschr</source><volume>113</volume><year>2006</year><fpage>157</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">16716052</pub-id></element-citation></ref><ref id="bib0540"><label>28</label><element-citation publication-type="journal" id="sbref0540"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>N.C.</given-names></name></person-group><article-title>An update on feline infectious peritonitis: virology and immunopathogenesis</article-title><source>Vet J</source><volume>201</volume><year>2014</year><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">24837550</pub-id></element-citation></ref><ref id="bib0545"><label>29</label><element-citation publication-type="journal" id="sbref0545"><person-group person-group-type="author"><name><surname>Vennema</surname><given-names>H.</given-names></name><name><surname>de Groot</surname><given-names>R.J.</given-names></name><name><surname>Harbour</surname><given-names>D.A.</given-names></name><name><surname>Dalderup</surname><given-names>M.</given-names></name><name><surname>Gruffydd-Jones</surname><given-names>T.</given-names></name><name><surname>Horzinek</surname><given-names>M.C.</given-names></name><name><surname>Spaan</surname><given-names>W.J.</given-names></name></person-group><article-title>Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization</article-title><source>J Virol</source><volume>64</volume><year>1990</year><fpage>1407</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">2154621</pub-id></element-citation></ref><ref id="bib0550"><label>30</label><element-citation publication-type="journal" id="sbref0550"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.Y.</given-names></name><name><surname>Werner</surname><given-names>H.C.</given-names></name><name><surname>Kong</surname><given-names>W.P.</given-names></name><name><surname>Leung</surname><given-names>K.</given-names></name><name><surname>Traggiai</surname><given-names>E.</given-names></name><name><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name><surname>Nabel</surname><given-names>G.J.</given-names></name></person-group><article-title>Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses</article-title><source>Proc Natl Acad Sci U S A</source><volume>102</volume><year>2005</year><fpage>797</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">15642942</pub-id></element-citation></ref><ref id="bib0555"><label>31</label><element-citation publication-type="journal" id="sbref0555"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chakraborti</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Sheahan</surname><given-names>T.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name></person-group><article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</article-title><source>Proc Natl Acad Sci U S A</source><volume>104</volume><year>2007</year><fpage>12123</fpage><lpage>12128</lpage><pub-id pub-id-type="pmid">17620608</pub-id></element-citation></ref><ref id="bib0560"><label>32</label><element-citation publication-type="journal" id="sbref0560"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Murakami</surname><given-names>A.</given-names></name><name><surname>Tamin</surname><given-names>A.</given-names></name><name><surname>Matthews</surname><given-names>L.J.</given-names></name><name><surname>Wong</surname><given-names>S.K.</given-names></name></person-group><article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><year>2004</year><fpage>2536</fpage><lpage>2541</lpage><pub-id pub-id-type="pmid">14983044</pub-id></element-citation></ref><ref id="bib0565"><label>33</label><element-citation publication-type="journal" id="sbref0565"><person-group person-group-type="author"><name><surname>Traggiai</surname><given-names>E.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><name><surname>Kolesnikova</surname><given-names>L.</given-names></name><name><surname>Uematsu</surname><given-names>Y.</given-names></name><name><surname>Gismondo</surname><given-names>M.R.</given-names></name></person-group><article-title>An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus</article-title><source>Nat Med</source><volume>10</volume><year>2004</year><fpage>871</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">15247913</pub-id></element-citation></ref><ref id="bib0570"><label>34</label><element-citation publication-type="journal" id="sbref0570"><person-group person-group-type="author"><name><surname>Stockman</surname><given-names>L.J.</given-names></name><name><surname>Bellamy</surname><given-names>R.</given-names></name><name><surname>Garner</surname><given-names>P.</given-names></name></person-group><article-title>SARS: systematic review of treatment effects</article-title><source>PLoS Med</source><volume>3</volume><year>2006</year><fpage>e343</fpage><pub-id pub-id-type="pmid">16968120</pub-id></element-citation></ref><ref id="bib0575"><label>35</label><element-citation publication-type="journal" id="sbref0575"><person-group person-group-type="author"><name><surname>Mair-Jenkins</surname><given-names>J.</given-names></name><name><surname>Saavedra-Campos</surname><given-names>M.</given-names></name><name><surname>Baillie</surname><given-names>J.K.</given-names></name><name><surname>Cleary</surname><given-names>P.</given-names></name><name><surname>Khaw</surname><given-names>F.M.</given-names></name><name><surname>Lim</surname><given-names>W.S.</given-names></name></person-group><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis</article-title><source>J Infect Dis</source><volume>211</volume><year>2015</year><fpage>80</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">25030060</pub-id></element-citation></ref><ref id="bib0580"><label>36</label><element-citation publication-type="journal" id="sbref0580"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Zuo</surname><given-names>T.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Poon</surname><given-names>K.M.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein</article-title><source>Sci Transl Med</source><volume>6</volume><year>2014</year><fpage>234ra259</fpage></element-citation></ref><ref id="bib0585"><label>37</label><element-citation publication-type="journal" id="sbref0585"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X.C.</given-names></name><name><surname>Agnihothram</surname><given-names>S.S.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Stanhope</surname><given-names>J.</given-names></name><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Peterson</surname><given-names>E.C.</given-names></name></person-group><article-title>Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution</article-title><source>Proc Natl Acad Sci U S A</source><volume>111</volume><year>2014</year><fpage>E2018</fpage><lpage>E2026</lpage><pub-id pub-id-type="pmid">24778221</pub-id></element-citation></ref><ref id="bib0590"><label>38</label><element-citation publication-type="journal" id="sbref0590"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Ju</surname><given-names>T.W.</given-names></name><name><surname>Prabakaran</surname><given-names>P.</given-names></name><name><surname>Lau</surname><given-names>C.C.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name></person-group><article-title>Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies</article-title><source>J Virol</source><volume>88</volume><year>2014</year><fpage>7796</fpage><lpage>7805</lpage><pub-id pub-id-type="pmid">24789777</pub-id></element-citation></ref><ref id="bib0595"><label>39</label><element-citation publication-type="journal" id="sbref0595"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Pedotti</surname><given-names>M.</given-names></name><name><surname>Simonelli</surname><given-names>L.</given-names></name><name><surname>Agnihothram</surname><given-names>S.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name></person-group><article-title>Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus</article-title><source>Proc Natl Acad Sci U S A</source><volume>112</volume><year>2015</year><fpage>10473</fpage><lpage>10478</lpage><pub-id pub-id-type="pmid">26216974</pub-id></element-citation></ref><ref id="bib0600"><label>40</label><element-citation publication-type="journal" id="sbref0600"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name><surname>Agnihothram</surname><given-names>S.S.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name></person-group><article-title>Rapid generation of a mouse model for Middle East respiratory syndrome</article-title><source>Proc Natl Acad Sci U S A</source><volume>111</volume><year>2014</year><fpage>4970</fpage><lpage>4975</lpage><pub-id pub-id-type="pmid">24599590</pub-id></element-citation></ref><ref id="bib0605"><label>41</label><element-citation publication-type="journal" id="sbref0605"><person-group person-group-type="author"><name><surname>Pascal</surname><given-names>K.E.</given-names></name><name><surname>Coleman</surname><given-names>C.M.</given-names></name><name><surname>Mujica</surname><given-names>A.O.</given-names></name><name><surname>Kamat</surname><given-names>V.</given-names></name><name><surname>Badithe</surname><given-names>A.</given-names></name><name><surname>Fairhurst</surname><given-names>J.</given-names></name></person-group><article-title>Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection</article-title><source>Proc Natl Acad Sci U S A</source><volume>112</volume><year>2015</year><fpage>8738</fpage><lpage>8743</lpage><pub-id pub-id-type="pmid">26124093</pub-id></element-citation></ref><ref id="bib0610"><label>42</label><element-citation publication-type="journal" id="sbref0610"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Perera</surname><given-names>R.A.</given-names></name><name><surname>Kayali</surname><given-names>G.</given-names></name><name><surname>Meyerholz</surname><given-names>D.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Peiris</surname><given-names>M.</given-names></name></person-group><article-title>Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection</article-title><source>J Virol</source><volume>89</volume><year>2015</year><fpage>6117</fpage><lpage>6120</lpage><pub-id pub-id-type="pmid">25787284</pub-id></element-citation></ref><ref id="bib0615"><label>43</label><element-citation publication-type="journal" id="sbref0615"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>J.E.</given-names></name><name><surname>Louder</surname><given-names>M.K.</given-names></name><name><surname>Holman</surname><given-names>L.A.</given-names></name><name><surname>Gordon</surname><given-names>I.J.</given-names></name><name><surname>Enama</surname><given-names>M.E.</given-names></name><name><surname>Larkin</surname><given-names>B.D.</given-names></name></person-group><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>6338</fpage><lpage>6343</lpage><pub-id pub-id-type="pmid">18824060</pub-id></element-citation></ref><ref id="bib0620"><label>44</label><element-citation publication-type="journal" id="sbref0620"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.Y.</given-names></name><name><surname>Kong</surname><given-names>W.P.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Murphy</surname><given-names>B.R.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><name><surname>Nabel</surname><given-names>G.J.</given-names></name></person-group><article-title>A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice</article-title><source>Nature</source><volume>428</volume><year>2004</year><fpage>561</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">15024391</pub-id></element-citation></ref><ref id="bib0625"><label>45</label><element-citation publication-type="journal" id="sbref0625"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.T.</given-names></name><name><surname>Zhang</surname><given-names>J.S.</given-names></name><name><surname>Su</surname><given-names>N.</given-names></name><name><surname>Xu</surname><given-names>J.G.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>J.T.</given-names></name></person-group><article-title>Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine</article-title><source>Antivir Ther</source><volume>12</volume><year>2007</year><fpage>1107</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">18018769</pub-id></element-citation></ref><ref id="bib0630"><label>46</label><element-citation publication-type="journal" id="sbref0630"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Siddiqui</surname><given-names>P.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry</article-title><source>Biochem Biophys Res Commun</source><volume>325</volume><year>2004</year><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">15530413</pub-id></element-citation></ref><ref id="bib0635"><label>47</label><element-citation publication-type="journal" id="sbref0635"><person-group person-group-type="author"><name><surname>Bolles</surname><given-names>M.</given-names></name><name><surname>Deming</surname><given-names>D.</given-names></name><name><surname>Long</surname><given-names>K.</given-names></name><name><surname>Agnihothram</surname><given-names>S.</given-names></name><name><surname>Whitmore</surname><given-names>A.</given-names></name><name><surname>Ferris</surname><given-names>M.</given-names></name></person-group><article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title><source>J Virol</source><volume>85</volume><year>2011</year><fpage>12201</fpage><lpage>12215</lpage><pub-id pub-id-type="pmid">21937658</pub-id></element-citation></ref><ref id="bib0640"><label>48</label><element-citation publication-type="journal" id="sbref0640"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>C.T.</given-names></name><name><surname>Sbrana</surname><given-names>E.</given-names></name><name><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name><surname>Newman</surname><given-names>P.C.</given-names></name><name><surname>Garron</surname><given-names>T.</given-names></name><name><surname>Atmar</surname><given-names>R.L.</given-names></name></person-group><article-title>Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><fpage>e35421</fpage><pub-id pub-id-type="pmid">22536382</pub-id></element-citation></ref><ref id="bib0645"><label>49</label><element-citation publication-type="journal" id="sbref0645"><person-group person-group-type="author"><name><surname>Almazan</surname><given-names>F.</given-names></name><name><surname>Dediego</surname><given-names>M.L.</given-names></name><name><surname>Galan</surname><given-names>C.</given-names></name><name><surname>Escors</surname><given-names>D.</given-names></name><name><surname>Alvarez</surname><given-names>E.</given-names></name><name><surname>Ortego</surname><given-names>J.</given-names></name></person-group><article-title>Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis</article-title><source>J Virol</source><volume>80</volume><year>2006</year><fpage>10900</fpage><lpage>10906</lpage><pub-id pub-id-type="pmid">16928748</pub-id></element-citation></ref><ref id="bib0650"><label>50</label><element-citation publication-type="journal" id="sbref0650"><person-group person-group-type="author"><name><surname>Yount</surname><given-names>B.</given-names></name><name><surname>Curtis</surname><given-names>K.M.</given-names></name><name><surname>Fritz</surname><given-names>E.A.</given-names></name><name><surname>Hensley</surname><given-names>L.E.</given-names></name><name><surname>Jahrling</surname><given-names>P.B.</given-names></name><name><surname>Prentice</surname><given-names>E.</given-names></name></person-group><article-title>Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus</article-title><source>Proc Natl Acad Sci U S A</source><volume>100</volume><year>2003</year><fpage>12995</fpage><lpage>13000</lpage><pub-id pub-id-type="pmid">14569023</pub-id></element-citation></ref><ref id="bib0655"><label>51</label><element-citation publication-type="journal" id="sbref0655"><person-group person-group-type="author"><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Alvarez</surname><given-names>E.</given-names></name><name><surname>Almazan</surname><given-names>F.</given-names></name><name><surname>Rejas</surname><given-names>M.T.</given-names></name><name><surname>Lamirande</surname><given-names>E.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name></person-group><article-title>A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo</article-title><source>J Virol</source><volume>81</volume><year>2007</year><fpage>1701</fpage><lpage>1713</lpage><pub-id pub-id-type="pmid">17108030</pub-id></element-citation></ref><ref id="bib0660"><label>52</label><element-citation publication-type="journal" id="sbref0660"><person-group person-group-type="author"><name><surname>Lamirande</surname><given-names>E.W.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Jackson</surname><given-names>J.P.</given-names></name><name><surname>Alvarez</surname><given-names>E.</given-names></name><name><surname>Sheahan</surname><given-names>T.</given-names></name></person-group><article-title>A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters</article-title><source>J Virol</source><volume>82</volume><year>2008</year><fpage>7721</fpage><lpage>7724</lpage><pub-id pub-id-type="pmid">18463152</pub-id></element-citation></ref><ref id="bib0665"><label>53</label><element-citation publication-type="journal" id="sbref0665"><person-group person-group-type="author"><name><surname>Netland</surname><given-names>J.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>Alvarez</surname><given-names>E.</given-names></name><name><surname>Nieto-Torres</surname><given-names>J.L.</given-names></name></person-group><article-title>Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease</article-title><source>Virology</source><volume>399</volume><year>2010</year><fpage>120</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">20110095</pub-id></element-citation></ref><ref id="bib0670"><label>54</label><element-citation publication-type="journal" id="sbref0670"><person-group person-group-type="author"><name><surname>Jimenez-Guardeno</surname><given-names>J.M.</given-names></name><name><surname>Regla-Nava</surname><given-names>J.A.</given-names></name><name><surname>Nieto-Torres</surname><given-names>J.L.</given-names></name><name><surname>DeDiego</surname><given-names>M.L.</given-names></name><name><surname>Castano-Rodriguez</surname><given-names>C.</given-names></name><name><surname>Fernandez-Delgado</surname><given-names>R.</given-names></name></person-group><article-title>Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine</article-title><source>PLoS Pathog</source><volume>11</volume><year>2015</year><fpage>e1005215</fpage><pub-id pub-id-type="pmid">26513244</pub-id></element-citation></ref><ref id="bib0675"><label>55</label><element-citation publication-type="journal" id="sbref0675"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Becker</surname><given-names>M.M.</given-names></name><name><surname>Eckerle</surname><given-names>L.D.</given-names></name><name><surname>Bolles</surname><given-names>M.</given-names></name><name><surname>Denison</surname><given-names>M.R.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease</article-title><source>Nat Med</source><volume>18</volume><year>2012</year><fpage>1820</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">23142821</pub-id></element-citation></ref><ref id="bib0680"><label>56</label><element-citation publication-type="journal" id="sbref0680"><person-group person-group-type="author"><name><surname>Yount</surname><given-names>B.</given-names></name><name><surname>Roberts</surname><given-names>R.S.</given-names></name><name><surname>Lindesmith</surname><given-names>L.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome</article-title><source>Proc Natl Acad Sci U S A</source><volume>103</volume><year>2006</year><fpage>12546</fpage><lpage>12551</lpage><pub-id pub-id-type="pmid">16891412</pub-id></element-citation></ref><ref id="bib0685"><label>57</label><element-citation publication-type="journal" id="sbref0685"><person-group person-group-type="author"><name><surname>Zust</surname><given-names>R.</given-names></name><name><surname>Cervantes-Barragan</surname><given-names>L.</given-names></name><name><surname>Kuri</surname><given-names>T.</given-names></name><name><surname>Blakqori</surname><given-names>G.</given-names></name><name><surname>Weber</surname><given-names>F.</given-names></name><name><surname>Ludewig</surname><given-names>B.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name></person-group><article-title>Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines</article-title><source>PLoS Pathog</source><volume>3</volume><year>2007</year><fpage>e109</fpage><pub-id pub-id-type="pmid">17696607</pub-id></element-citation></ref><ref id="bib0690"><label>58</label><element-citation publication-type="journal" id="sbref0690"><person-group person-group-type="author"><name><surname>Bisht</surname><given-names>H.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Vogel</surname><given-names>L.</given-names></name><name><surname>Bukreyev</surname><given-names>A.</given-names></name><name><surname>Collins</surname><given-names>P.L.</given-names></name><name><surname>Murphy</surname><given-names>B.R.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><year>2004</year><fpage>6641</fpage><lpage>6646</lpage><pub-id pub-id-type="pmid">15096611</pub-id></element-citation></ref><ref id="bib0695"><label>59</label><element-citation publication-type="journal" id="sbref0695"><person-group person-group-type="author"><name><surname>See</surname><given-names>R.H.</given-names></name><name><surname>Petric</surname><given-names>M.</given-names></name><name><surname>Lawrence</surname><given-names>D.J.</given-names></name><name><surname>Mok</surname><given-names>C.P.</given-names></name><name><surname>Rowe</surname><given-names>T.</given-names></name><name><surname>Zitzow</surname><given-names>L.A.</given-names></name></person-group><article-title>Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines</article-title><source>J Gen Virol</source><volume>89</volume><year>2008</year><fpage>2136</fpage><lpage>2146</lpage><pub-id pub-id-type="pmid">18753223</pub-id></element-citation></ref><ref id="bib0700"><label>60</label><element-citation publication-type="journal" id="sbref0700"><person-group person-group-type="author"><name><surname>Kobinger</surname><given-names>G.P.</given-names></name><name><surname>Figueredo</surname><given-names>J.M.</given-names></name><name><surname>Rowe</surname><given-names>T.</given-names></name><name><surname>Zhi</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Sanmiguel</surname><given-names>J.C.</given-names></name></person-group><article-title>Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques</article-title><source>Vaccine</source><volume>25</volume><year>2007</year><fpage>5220</fpage><lpage>5231</lpage><pub-id pub-id-type="pmid">17559989</pub-id></element-citation></ref><ref id="bib0705"><label>61</label><element-citation publication-type="journal" id="sbref0705"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Sui</surname><given-names>H.</given-names></name><name><surname>Chan</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name></person-group><article-title>Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection</article-title><source>J Immunol</source><volume>180</volume><year>2008</year><fpage>948</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">18178835</pub-id></element-citation></ref><ref id="bib0710"><label>62</label><element-citation publication-type="journal" id="sbref0710"><person-group person-group-type="author"><name><surname>Bukreyev</surname><given-names>A.</given-names></name><name><surname>Lamirande</surname><given-names>E.W.</given-names></name><name><surname>Buchholz</surname><given-names>U.J.</given-names></name><name><surname>Vogel</surname><given-names>L.N.</given-names></name><name><surname>Elkins</surname><given-names>W.R.</given-names></name><name><surname>St Claire</surname><given-names>M.</given-names></name></person-group><article-title>Mucosal immunisation of African green monkeys (<italic>Cercopithecus aethiops</italic>) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS</article-title><source>Lancet</source><volume>363</volume><year>2004</year><fpage>2122</fpage><lpage>2127</lpage><pub-id pub-id-type="pmid">15220033</pub-id></element-citation></ref><ref id="bib0715"><label>63</label><element-citation publication-type="journal" id="sbref0715"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>M.</given-names></name><name><surname>Lamirande</surname><given-names>E.W.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Rice</surname><given-names>A.B.</given-names></name><name><surname>Koprowski</surname><given-names>H.</given-names></name><name><surname>Dietzschold</surname><given-names>B.</given-names></name><name><surname>Schnell</surname><given-names>M.J.</given-names></name></person-group><article-title>A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies</article-title><source>J Gen Virol</source><volume>86</volume><year>2005</year><fpage>1435</fpage><lpage>1440</lpage><pub-id pub-id-type="pmid">15831955</pub-id></element-citation></ref><ref id="bib0720"><label>64</label><element-citation publication-type="journal" id="sbref0720"><person-group person-group-type="author"><name><surname>Escriou</surname><given-names>N.</given-names></name><name><surname>Callendret</surname><given-names>B.</given-names></name><name><surname>Lorin</surname><given-names>V.</given-names></name><name><surname>Combredet</surname><given-names>C.</given-names></name><name><surname>Marianneau</surname><given-names>P.</given-names></name><name><surname>Fevrier</surname><given-names>M.</given-names></name><name><surname>Tangy</surname><given-names>F.</given-names></name></person-group><article-title>Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein</article-title><source>Virology</source><volume>452–453</volume><year>2014</year><fpage>32</fpage><lpage>41</lpage></element-citation></ref><ref id="bib0725"><label>65</label><element-citation publication-type="journal" id="sbref0725"><person-group person-group-type="author"><name><surname>Liniger</surname><given-names>M.</given-names></name><name><surname>Zuniga</surname><given-names>A.</given-names></name><name><surname>Tamin</surname><given-names>A.</given-names></name><name><surname>Azzouz-Morin</surname><given-names>T.N.</given-names></name><name><surname>Knuchel</surname><given-names>M.</given-names></name><name><surname>Marty</surname><given-names>R.R.</given-names></name></person-group><article-title>Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses</article-title><source>Vaccine</source><volume>26</volume><year>2008</year><fpage>2164</fpage><lpage>2174</lpage><pub-id pub-id-type="pmid">18346823</pub-id></element-citation></ref><ref id="bib0730"><label>66</label><element-citation publication-type="journal" id="sbref0730"><person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>S.U.</given-names></name><name><surname>Simon</surname><given-names>I.D.</given-names></name><name><surname>Rose</surname><given-names>J.K.</given-names></name></person-group><article-title>SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector</article-title><source>Virology</source><volume>376</volume><year>2008</year><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">18396306</pub-id></element-citation></ref><ref id="bib0735"><label>67</label><element-citation publication-type="journal" id="sbref0735"><person-group person-group-type="author"><name><surname>Deming</surname><given-names>D.</given-names></name><name><surname>Sheahan</surname><given-names>T.</given-names></name><name><surname>Heise</surname><given-names>M.</given-names></name><name><surname>Yount</surname><given-names>B.</given-names></name><name><surname>Davis</surname><given-names>N.</given-names></name><name><surname>Sims</surname><given-names>A.</given-names></name></person-group><article-title>Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants</article-title><source>PLoS Med</source><volume>3</volume><year>2006</year><fpage>e525</fpage><pub-id pub-id-type="pmid">17194199</pub-id></element-citation></ref><ref id="bib0740"><label>68</label><element-citation publication-type="journal" id="sbref0740"><person-group person-group-type="author"><name><surname>Yasui</surname><given-names>F.</given-names></name><name><surname>Kai</surname><given-names>C.</given-names></name><name><surname>Kitabatake</surname><given-names>M.</given-names></name><name><surname>Inoue</surname><given-names>S.</given-names></name><name><surname>Yoneda</surname><given-names>M.</given-names></name><name><surname>Yokochi</surname><given-names>S.</given-names></name></person-group><article-title>Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV</article-title><source>J Immunol</source><volume>181</volume><year>2008</year><fpage>6337</fpage><lpage>6348</lpage><pub-id pub-id-type="pmid">18941225</pub-id></element-citation></ref><ref id="bib0745"><label>69</label><element-citation publication-type="journal" id="sbref0745"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>G.</given-names></name><name><surname>Chan</surname><given-names>C.C.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and <italic>E. coli</italic> cells elicits potent neutralizing antibody and protective immunity</article-title><source>Virology</source><volume>393</volume><year>2009</year><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">19683779</pub-id></element-citation></ref><ref id="bib0750"><label>70</label><element-citation publication-type="journal" id="sbref0750"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Okada</surname><given-names>K.</given-names></name><name><surname>Kenniston</surname><given-names>T.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>AlHajri</surname><given-names>M.M.</given-names></name><name><surname>Farag</surname><given-names>E.A.</given-names></name></person-group><article-title>Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>5975</fpage><lpage>5982</lpage><pub-id pub-id-type="pmid">25192975</pub-id></element-citation></ref><ref id="bib0755"><label>71</label><element-citation publication-type="journal" id="sbref0755"><person-group person-group-type="author"><name><surname>Volz</surname><given-names>A.</given-names></name><name><surname>Kupke</surname><given-names>A.</given-names></name><name><surname>Song</surname><given-names>F.</given-names></name><name><surname>Jany</surname><given-names>S.</given-names></name><name><surname>Fux</surname><given-names>R.</given-names></name><name><surname>Shams-Eldin</surname><given-names>H.</given-names></name></person-group><article-title>Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein</article-title><source>J Virol</source><volume>89</volume><year>2015</year><fpage>8651</fpage><lpage>8656</lpage><pub-id pub-id-type="pmid">26018172</pub-id></element-citation></ref><ref id="bib0760"><label>72</label><element-citation publication-type="journal" id="sbref0760"><person-group person-group-type="author"><name><surname>Malczyk</surname><given-names>A.H.</given-names></name><name><surname>Kupke</surname><given-names>A.</given-names></name><name><surname>Prufer</surname><given-names>S.</given-names></name><name><surname>Scheuplein</surname><given-names>V.A.</given-names></name><name><surname>Hutzler</surname><given-names>S.</given-names></name><name><surname>Kreuz</surname><given-names>D.</given-names></name></person-group><article-title>A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform</article-title><source>J Virol</source><volume>89</volume><year>2015</year><fpage>11654</fpage><lpage>11667</lpage><pub-id pub-id-type="pmid">26355094</pub-id></element-citation></ref><ref id="bib0765"><label>73</label><element-citation publication-type="journal" id="sbref0765"><person-group person-group-type="author"><name><surname>Muthumani</surname><given-names>K.</given-names></name><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>Reuschel</surname><given-names>E.L.</given-names></name><name><surname>Tingey</surname><given-names>C.</given-names></name><name><surname>Flingai</surname><given-names>S.</given-names></name><name><surname>Villarreal</surname><given-names>D.O.</given-names></name></person-group><article-title>A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates</article-title><source>Sci Transl Med</source><volume>7</volume><year>2015</year><fpage>301ra132</fpage></element-citation></ref><ref id="bib0770"><label>74</label><element-citation publication-type="journal" id="sbref0770"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge</article-title><source>EBioMedicine</source><volume>2</volume><year>2015</year><fpage>1438</fpage><lpage>1446</lpage><pub-id pub-id-type="pmid">26629538</pub-id></element-citation></ref><ref id="bib0775"><label>75</label><element-citation publication-type="journal" id="sbref0775"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Receptor-binding domain-based subunit vaccines against MERS-CoV</article-title><source>Virus Res</source><volume>202</volume><year>2015</year><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">25445336</pub-id></element-citation></ref><ref id="bib0780"><label>76</label><element-citation publication-type="journal" id="sbref0780"><person-group person-group-type="author"><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>van den Brand</surname><given-names>J.M.</given-names></name><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Volz</surname><given-names>A.</given-names></name><name><surname>Wohlsein</surname><given-names>P.</given-names></name><name><surname>Smits</surname><given-names>S.L.</given-names></name></person-group><article-title>An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels</article-title><source>Science</source><volume>351</volume><year>2015</year><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">26678878</pub-id></element-citation></ref><ref id="bib0785"><label>77</label><element-citation publication-type="journal" id="sbref0785"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>X.Y.</given-names></name><name><surname>Li</surname><given-names>J.L.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Chmura</surname><given-names>A.A.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>Epstein</surname><given-names>J.H.</given-names></name></person-group><article-title>Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor</article-title><source>Nature</source><volume>503</volume><year>2013</year><fpage>535</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">24172901</pub-id></element-citation></ref><ref id="bib0790"><label>78</label><element-citation publication-type="journal" id="sbref0790"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>V.D.</given-names></name><name><surname>Yount</surname><given-names>B.L.</given-names><suffix>Jr.</suffix></name><name><surname>Debbink</surname><given-names>K.</given-names></name><name><surname>Agnihothram</surname><given-names>S.</given-names></name><name><surname>Gralinski</surname><given-names>L.E.</given-names></name><name><surname>Plante</surname><given-names>J.A.</given-names></name></person-group><article-title>A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence</article-title><source>Nat Med</source><volume>21</volume><year>2015</year><fpage>1508</fpage><lpage>1513</lpage><pub-id pub-id-type="pmid">26552008</pub-id></element-citation></ref><ref id="bib0795"><label>79</label><element-citation publication-type="journal" id="sbref0795"><person-group person-group-type="author"><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>de Wit</surname><given-names>E.</given-names></name><name><surname>Feldmann</surname><given-names>F.</given-names></name><name><surname>Rasmussen</surname><given-names>A.L.</given-names></name><name><surname>Okumura</surname><given-names>A.</given-names></name><name><surname>Peng</surname><given-names>X.</given-names></name></person-group><article-title>Infection with MERS-CoV causes lethal pneumonia in the common marmoset</article-title><source>PLoS Pathog</source><volume>10</volume><year>2014</year><fpage>e1004250</fpage><pub-id pub-id-type="pmid">25144235</pub-id></element-citation></ref><ref id="bib0800"><label>80</label><element-citation publication-type="journal" id="sbref0800"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>R.F.</given-names></name><name><surname>Via</surname><given-names>L.E.</given-names></name><name><surname>Kumar</surname><given-names>M.R.</given-names></name><name><surname>Cornish</surname><given-names>J.P.</given-names></name><name><surname>Yellayi</surname><given-names>S.</given-names></name><name><surname>Huzella</surname><given-names>L.</given-names></name></person-group><article-title>Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease</article-title><source>Virology</source><volume>485</volume><year>2015</year><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">26342468</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements</title><p>Supported in part by grants from the National Institutes of Health, USA (RO1 AI091322 and PO1 AI060699).</p><p><italic>Conflict of interest:</italic> The authors report no conflicts of interest, financial or otherwise.</p></ack></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000D59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:4969153
|texte= Middle East respiratory syndrome vaccines
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:27062985" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |